YouTube2Text

Elizabeth Holmes SEC Deposition JULY 11, 2017 2 OF 4 redacted — Transcript

by ANTL Media · 16,016 words · 2,977 segments · language en · Watch on YouTube

Full transcript

  1. 0:03We are back on the record at the
  2. 0:05beginning of media number two of
  3. 0:07Elizabeth Holmes. The time is 10:30.
  4. 0:10And Ms. Holmes, I just wanted to confirm
  5. 0:13we didn't have any substantive
  6. 0:15conversations during the break, did we?
  7. 0:17No.
  8. 0:18Okay, and I just want to make that
  9. 0:20give you that question after every break
  10. 0:22just to make sure that nothing was said
  11. 0:24off the record.
  12. 0:24Absolutely.
  13. 0:25Okay, so I'm going to hand to you what's
  14. 0:27been marked as Theranos so that 195.
  15. 0:38For everyone else this is 10.
  16. 0:47Exhibit 195
  17. 0:49purports to be
  18. 0:50a document entitled Theranos
  19. 0:52Confidential Summary Capitalization.
  20. 0:55The starting Bates number is TS-000603.
  21. 1:00I'll represent to you that this was
  22. 1:02produced by Theranos to the SEC as part
  23. 1:05of a binder that was provided by
  24. 1:07Theranos to Rupert Murdoch when he was
  25. 1:08considering whether to invest in
  26. 1:10Theranos in December 2014 and January
  27. 1:132015.
  28. 1:14The cover letter to the binder states
  29. 1:16that it was signed as of December 4th,
  30. 1:182014.
  31. 1:20You seen exhibit 195 before?
  32. 1:25You know, I I didn't recognize this
  33. 1:27first sheet sitting here now, but I'm
  34. 1:29I'm sure I did.
  35. 1:31What is exhibit 195?
  36. 1:35Um, it looks like our cap table
  37. 1:38and behind it a series of projections.
  38. 1:47Did you review exhibit 195 on or about
  39. 1:51December 4th, 2014?
  40. 1:55Um,
  41. 1:57I know I I don't
  42. 1:59have memory of
  43. 2:00whether I reviewed it at that time, but
  44. 2:02I I know I've seen it.
  45. 2:05So, I'm actually
  46. 2:06just going to start on the first page,
  47. 2:08which is 603. Is the Bates number at the
  48. 2:11bottom?
  49. 2:12Yes.
  50. 2:12Uh is this an accurate reflection of
  51. 2:14Theranos' capital raising since it's um
  52. 2:17since the company
  53. 2:19was founded?
  54. 2:23As of what period of time?
  55. 2:26Um I guess as of 2013. That's a good
  56. 2:28date.
  57. 2:30As of 2013.
  58. 2:32Um
  59. 2:37No.
  60. 2:39Um
  61. 2:41I think this was as of
  62. 2:43a later period of time.
  63. 2:46Okay. So, what period What was the date
  64. 2:49at which do you this document was
  65. 2:50prepared at then?
  66. 2:52The the C2 didn't happen until
  67. 2:55um
  68. 2:572014 was the first part of the C2.
  69. 3:02Okay. So,
  70. 3:03um so you think that this is an accurate
  71. 3:05reflection of the capital raising the
  72. 3:07company did as of 2014?
  73. 3:09No.
  74. 3:11No.
  75. 3:12No.
  76. 3:12Okay. So,
  77. 3:14what happened in 2014?
  78. 3:17Oh, I'm sorry. As of 2014, I was missing
  79. 3:19my years. Yes, I think that as of the
  80. 3:21end of 2014, this this looks about
  81. 3:23right.
  82. 3:23This looks about right. But how much was
  83. 3:25raised during the C2 round?
  84. 3:29Um it was it was several hundred million
  85. 3:31dollars. I I don't know exactly the a
  86. 3:33number. Um
  87. 3:36I I think it was it was over 500
  88. 3:37million.
  89. 3:38Okay. So, if it was over 500 million,
  90. 3:40then um
  91. 3:42do you think that this chart maybe isn't
  92. 3:44an accurate reflection at least um it
  93. 3:46doesn't include some of the C2 round?
  94. 3:49Um correct. It doesn't include some of
  95. 3:51the C2. I I don't know exactly when this
  96. 3:53was prepared and what period of time it
  97. 3:55was supposed to be reflective of.
  98. 3:57Okay.
  99. 3:58Um but you think that the the total for
  100. 4:00the C2 round would have been something
  101. 4:02like over 500 million dollars.
  102. 4:04I believe so.
  103. 4:07Um so I just want to focus for a period
  104. 4:11uh
  105. 4:12on the C1 and C2 rounds.
  106. 4:15What were those financing rounds? What
  107. 4:17was the purpose of raising money during
  108. 4:19those rounds?
  109. 4:22Um
  110. 4:24so they were they were different at
  111. 4:26different points in time. C1
  112. 4:29uh we began
  113. 4:32developing strategic relationships with
  114. 4:35um
  115. 4:36long-term shareholders and um some of
  116. 4:39the hospital systems that we wanted to
  117. 4:41partner with came in through a fund and
  118. 4:45then C2 we had decided that we wanted to
  119. 4:48try to structure Theranos as a private
  120. 4:50company and we were looking for
  121. 4:54family-owned businesses or
  122. 4:55family-controlled companies um and
  123. 4:58leadership who
  124. 5:00wanted to invest in something for the
  125. 5:02really long term and we identified a
  126. 5:05group of people to try to bring in for
  127. 5:06that.
  128. 5:07So you said for C the C1 round, I just
  129. 5:10want to make sure that I understand. For
  130. 5:12the C1 round
  131. 5:14um that was mainly money coming from
  132. 5:16strategic partners like hospitals and
  133. 5:19When it started.
  134. 5:20Yes.
  135. 5:20Yeah, I mean it we had also um
  136. 5:23another family that invested through one
  137. 5:26of the funds that came in in in C1 and
  138. 5:30um then a couple of the hospital systems
  139. 5:33that we were hoping to partner with came
  140. 5:35in in that as well.
  141. 5:36Which family came in in C1 that you're
  142. 5:39thinking of?
  143. 5:39This family.
  144. 5:41And did family and uh the hospital
  145. 5:44systems they all come in through Peer
  146. 5:45Venture Group?
  147. 5:46They did.
  148. 5:46What is Pure Venture Group?
  149. 5:49It is a fund.
  150. 5:51Um
  151. 5:52what was your relationship with them?
  152. 5:55For a long time. And I I met him through
  153. 5:59Okay. And so how did that relationship
  154. 6:01come about?
  155. 6:03You know, who initiated talks of um
  156. 6:07uh
  157. 6:07part potentially investing in Theranos.
  158. 6:10Um you know, and what happened? How did
  159. 6:12you How did How were you able to get
  160. 6:14that investment from Pure Venture Group?
  161. 6:16The first one was in 2010. So I I don't
  162. 6:19remember specifically, but I My memory
  163. 6:22is that had expressed interest about
  164. 6:24investing in Theranos and specifically
  165. 6:27sort of having a fund that focused on
  166. 6:29investing in Theranos and strongly
  167. 6:31encouraged uh me to meet with him and
  168. 6:35the people that I think he was working
  169. 6:36to raise money from and um
  170. 6:39and to invest.
  171. 6:41Okay. And then you mentioned for C2,
  172. 6:44that was mainly for um
  173. 6:47you'd raise money in order to establish
  174. 6:49a long-term shareholder base. Is that
  175. 6:52right? Can you explain a little bit more
  176. 6:53about that?
  177. 6:54Yeah. Over over a period of time, we
  178. 6:57became convinced that becoming a private
  179. 6:59company for the long term would best
  180. 7:01allow us to do something that was going
  181. 7:03to be a very long-term
  182. 7:05venture. And so we were trying to find
  183. 7:07investors who wanted to invest in
  184. 7:10private companies and wanted to make
  185. 7:12really long-term investments and
  186. 7:15generally who had built family
  187. 7:16companies. And um so we identified a
  188. 7:19series of people who had done that and
  189. 7:22went to meet with them to talk about
  190. 7:25this vision. And And so that was That
  191. 7:27was the majority of the C2.
  192. 7:31What was the money that you raised
  193. 7:32during the C1 and C2 rounds used for?
  194. 7:36Um a lot of R&D and operational
  195. 7:41investments. Like we built a a big
  196. 7:44manufacturing facility in Newark,
  197. 7:46California where we do our own injection
  198. 7:48molding and machining and reagent
  199. 7:50production and um
  200. 7:54um
  201. 7:57primarily those two things.
  202. 8:00Going into both of these rounds of
  203. 8:01financing, did you have a particular
  204. 8:03target that you were aiming to raise?
  205. 8:06And what were those targets?
  206. 8:08I I don't I don't know. I'm I'm sure we
  207. 8:11did. I I can't remember exactly what the
  208. 8:14what the numbers were. Um I I think it
  209. 8:19it was also a bit dynamic in terms of
  210. 8:21responding to interest and people who
  211. 8:23had expressed interest in being
  212. 8:25shareholders in the company.
  213. 8:29So if you look um at the price at which
  214. 8:32the shares were sold during these two
  215. 8:35rounds, um the first C1 round that took
  216. 8:38place in 2010, the price was $3 a share.
  217. 8:43Uh the second C1 round, it went up to
  218. 8:45$15. What um
  219. 8:49what precipitated the the change in
  220. 8:50price?
  221. 8:54So my my memory is that that was um
  222. 8:58a a price per share that was established
  223. 9:02uh through the relationships with the
  224. 9:04retail pharmacy partners who were
  225. 9:06thinking about what the value of
  226. 9:08Theranos could be um if we had these
  227. 9:12retail frameworks in place and that
  228. 9:13that's where that that number came from.
  229. 9:17So are you are you saying then that the
  230. 9:19retail uh partners um actually valued
  231. 9:23Theranos at the $15 a share?
  232. 9:26I don't know if they valued it, but
  233. 9:29to the extent there were provisions in
  234. 9:32the contract that gave them potential
  235. 9:34rights to equity, that was the value
  236. 9:37that they put on the equity rights that
  237. 9:39they had.
  238. 9:40Who came up with the $15 per share
  239. 9:42valuation?
  240. 9:46I I don't I don't know.
  241. 9:48I'm not sure.
  242. 9:50Was that a number that Theranos
  243. 9:51requested of its retail partners?
  244. 9:57You know, I don't remember. I I know
  245. 9:59there was a lot of work with the retail
  246. 10:02partners to create models together of
  247. 10:04what this could be. I'm not sure if
  248. 10:08I'm not sure who who settled on that
  249. 10:10number in the end.
  250. 10:13Was it negotiated?
  251. 10:15I don't think so.
  252. 10:19Who would know the answer to that
  253. 10:20question?
  254. 10:23I mean, I'm assuming our team could look
  255. 10:26back at at documents and and try to
  256. 10:28figure it out. I
  257. 10:30I don't remember. Um
  258. 10:34I'm not sure.
  259. 10:35Would you have been involved in those
  260. 10:36discussions
  261. 10:38with your retail partners?
  262. 10:39I I would have, yes.
  263. 10:41Would Sunny Balwani have been involved?
  264. 10:42Yes.
  265. 10:49Okay.
  266. 10:50Um I'm going to hand you another
  267. 10:52document.
  268. 10:54You can put that one aside.
  269. 11:26I'm handing to you what's been marked as
  270. 11:28Theranos 608 196.
  271. 11:35Exhibit 196 purports to be
  272. 11:37uh a spreadsheet.
  273. 11:39Uh the title at the top is
  274. 11:42detailed um
  275. 11:442917.
  276. 11:45Starting base number is
  277. 11:48TS-0558077.
  278. 11:52Have you seen Exhibit 196 before?
  279. 11:57You know what? I don't remember seeing
  280. 11:58this version, but I I recognize it as as
  281. 12:02our cap table.
  282. 12:07Did you review Exhibit 196 on or around
  283. 12:10February 9th, 2017?
  284. 12:14I I don't remember doing that.
  285. 12:17I'll represent to you that that's the
  286. 12:19date at which um
  287. 12:21that appears on the document uh and
  288. 12:23would have been around the date that
  289. 12:24Theranos produced the document to the
  290. 12:26SEC.
  291. 12:27Yep.
  292. 12:28So,
  293. 12:30I want to focus on some of the C1 and C2
  294. 12:33investors on this list. So, if you go
  295. 12:35down, uh
  296. 12:37there's an investor called Bendel Fund.
  297. 12:39Do you see that on the first page?
  298. 12:43I do.
  299. 12:45Uh
  300. 12:46and they invested like
  301. 12:48in 249,998
  302. 12:51shares um in the C2 round.
  303. 12:54Who is the the Bendel Fund?
  304. 12:57Um I believe uh this is
  305. 13:01his he's an individual um company.
  306. 13:07How do you know him?
  307. 13:08How did you get to know him?
  308. 13:10I met him through this process of trying
  309. 13:12to find
  310. 13:14family
  311. 13:15controlled companies and investors um
  312. 13:17and
  313. 13:18I'm trying to remember who made the
  314. 13:20introduction. He he knows a number of
  315. 13:23people affiliated with the company um
  316. 13:26I'm not quite sure who made the the
  317. 13:28final introduction to him.
  318. 13:31Who does he know at the company?
  319. 13:34I'm
  320. 13:35He knows some of our investors. He knows
  321. 13:37some of our board members specifically.
  322. 13:40I
  323. 13:41I'm just not sure who who made the first
  324. 13:43introduction to him.
  325. 13:47Who are the investors that he knew?
  326. 13:49I I My understanding is he knows he
  327. 13:52knows most of our C2 investors, the
  328. 13:54other large family
  329. 13:55investors.
  330. 13:59What about Central Valley
  331. 14:00Administrators? Who are they?
  332. 14:05It's on the second page.
  333. 14:06I think that is that Walgreens
  334. 14:09introduced us to when they were talking
  335. 14:12about deploying in California.
  336. 14:16Who's
  337. 14:17Okay, and what Why was he
  338. 14:20interested in Theranos?
  339. 14:22I I think he really believes in I'm
  340. 14:27the need for lower cost, more
  341. 14:29distributed testing.
  342. 14:32Were you in talks to
  343. 14:35partner with him in any way?
  344. 14:37It was our hope that had we deployed in
  345. 14:40Los Angeles with Walgreens, we would
  346. 14:42work with his physician groups.
  347. 14:44So was this Was he also considered a
  348. 14:46strategic partner, a possible strategic
  349. 14:49partner?
  350. 14:49Yes.
  351. 14:51So in other words, even though he
  352. 14:52invested in the C2 round, it looks like
  353. 14:55there were also also opportunities for
  354. 14:57strategic partners to come in in the C2
  355. 14:59round in addition to some of these
  356. 15:00families.
  357. 15:02I'm
  358. 15:04I'm trying to think if there were any
  359. 15:05others beside him. I know generally the
  360. 15:07the focus of C2 was the families. I'm
  361. 15:12But had there been a
  362. 15:14a strategic I mean there's no reason why
  363. 15:16we wouldn't have looked at that in the
  364. 15:18context of involvement.
  365. 15:21If you turn the page to page three,
  366. 15:27uh, what about Dynasty Financial?
  367. 15:31It's also a C2 round investor.
  368. 15:33I I believe that's the DeVos family.
  369. 15:36It's the DeVos family. How did you know
  370. 15:38them?
  371. 15:40I met them uh
  372. 15:41at a
  373. 15:43um conference for family-controlled
  374. 15:46companies
  375. 15:47um and
  376. 15:49um
  377. 15:50I talked to him about our vision.
  378. 15:53What conference is that?
  379. 15:55That was the conference
  380. 15:58I think it was in Chicago.
  381. 16:00And what is So they invited a number of
  382. 16:02uh family offices to come for a
  383. 16:05conference?
  384. 16:06I I think so, yes.
  385. 16:07that happen?
  386. 16:09Um in the fall of 2014
  387. 16:13or maybe winter of 2014.
  388. 16:15Why did you attend?
  389. 16:17I was asked to speak at it.
  390. 16:18What did you speak about?
  391. 16:20had asked me to serve on a panel, I
  392. 16:22think about innovation. Um I I don't
  393. 16:24remember what I talked about. It was I'm
  394. 16:27sorry. Uh
  395. 16:28Uh you don't recall what you talked
  396. 16:29about at that conference?
  397. 16:32I don't. I mean I I guess. Um
  398. 16:35I don't remember it specifically.
  399. 16:36Did you meet uh the DeVos family at that
  400. 16:38conference?
  401. 16:39I did.
  402. 16:41Who was your main contact there?
  403. 16:44Um initially it was now it's
  404. 16:47He was
  405. 16:48She's my understanding and her boss.
  406. 16:50Is he or
  407. 16:52I I I think so. I'm not sure.
  408. 16:55Uh
  409. 16:55what about Hall Black Diamond 2, which
  410. 16:58is towards the bottom of the of page
  411. 17:00three?
  412. 17:03Um
  413. 17:04Who are they?
  414. 17:06So that is a fund that was created for
  415. 17:11one of the limited partners of Black
  416. 17:13Diamond to be able to have direct uh
  417. 17:16holdings in Theranos.
  418. 17:19And who
  419. 17:20Black Diamond and I I think a successful
  420. 17:22business person um
  421. 17:24How did you meet him?
  422. 17:27I I believe I met him after he had
  423. 17:30invested in Black Diamond's fund that
  424. 17:32invested in Theranos. Um so through
  425. 17:35Black Diamond.
  426. 17:36And um was there somebody else at Black
  427. 17:38Diamond that you knew prior to uh this
  428. 17:42relationship? Who
  429. 17:44Um
  430. 17:45If you turn the page to page four
  431. 17:49at the very top
  432. 17:51who is
  433. 17:52That is my understanding is it's the
  434. 17:55um foundation affiliated with his
  435. 17:58family.
  436. 17:59And who's
  437. 18:00Uh he's a a
  438. 18:02businessman.
  439. 18:03Um when did you first contact with him?
  440. 18:10Um
  441. 18:11I think in
  442. 18:132014.
  443. 18:15Um but I'm not completely sure.
  444. 18:18How did you meet him?
  445. 18:20I met him
  446. 18:22um
  447. 18:26I I I
  448. 18:28I think I met him at
  449. 18:31um someone's house and we started having
  450. 18:34a conversation about health care.
  451. 18:37Do you recall whose house you met him
  452. 18:39at?
  453. 18:40I think it was um
  454. 18:41a Silicon Valley venture capitalist.
  455. 18:45What did you talk about?
  456. 18:48We talked about the need to make lab
  457. 18:51testing lower cost and more accessible
  458. 18:53and um
  459. 18:56the need to
  460. 18:57invest in technologies
  461. 18:59that can leapfrog over traditional lab
  462. 19:03infrastructure kind of like cell phones
  463. 19:05did over landlines and how important
  464. 19:08that's going to be for for for care.
  465. 19:11Is he in the health care business?
  466. 19:14He is, yes.
  467. 19:16Uh
  468. 19:16what is his business?
  469. 19:18And also a number of other businesses.
  470. 19:22Um he owns retail grocery store. Um that
  471. 19:24include pharmacies um and
  472. 19:28many other businesses.
  473. 19:29Did you ever have any discussions with
  474. 19:32about uh partnering with his businesses?
  475. 19:35We did.
  476. 19:36And how did those
  477. 19:37how did those discussions go?
  478. 19:40They were very positive. Um he has a
  479. 19:43foundation that we've interacted with
  480. 19:45most closely that's talked to us about a
  481. 19:48number of different projects including
  482. 19:49our our current focus on on Zika virus
  483. 19:52testing in
  484. 19:54low-income and distributed areas.
  485. 19:56Did you end up entering into a contract
  486. 19:57with him or his companies?
  487. 20:00I I don't know if we have a contract
  488. 20:02with their foundation. I'm not sure.
  489. 20:06Not his his laboratory um business.
  490. 20:12Um
  491. 20:15Okay. Um
  492. 20:16let's turn page to
  493. 20:20page six.
  494. 20:25Towards the top of the page um there's
  495. 20:27an investor called Sandbox Financial
  496. 20:29Company Sandbox
  497. 20:31Co-Investment Fund.
  498. 20:33Who are they?
  499. 20:35So I think these are two different ones.
  500. 20:37Are they two different ones?
  501. 20:39Yeah.
  502. 20:43Okay, then I'm asking about Sandbox
  503. 20:45Co-Investment Fund since they're C1
  504. 20:46investor.
  505. 20:47Yes, so they are
  506. 20:50um
  507. 20:51as I understand it the fund that manages
  508. 20:54the investments for the Blue Cross Blue
  509. 20:56Shield Association.
  510. 20:58And how did you get in contact with
  511. 21:00them?
  512. 21:02So this was
  513. 21:03I think in 2010 and I
  514. 21:08I'm not sure. I think it was our board
  515. 21:10member Robert Shapiro was an advisor to
  516. 21:14the Blue Cross Blue Shield Association
  517. 21:16fund and part of Sandbox and I think he
  518. 21:18made the introduction. It
  519. 21:20may have come from somewhere else, um
  520. 21:22but
  521. 21:23that sounds right.
  522. 21:25What was your understanding of why they
  523. 21:27were interested in investing at
  524. 21:28Theranos?
  525. 21:30Because the lab companies have been
  526. 21:32charging them extremely high rates and
  527. 21:35they've been negotiating for years to
  528. 21:37try to break up the
  529. 21:39um
  530. 21:40duopoly of pricing between Quest and
  531. 21:42LabCorp and they thought that we could
  532. 21:44build a low a lab company that would
  533. 21:47offer really low cost testing.
  534. 21:52And then further down the page, um Soda
  535. 21:55Spring Partners.
  536. 21:58Who are they?
  537. 22:00That is Alice Walton, part of the Walton
  538. 22:02family.
  539. 22:03Part of the Walton family. And how did
  540. 22:04you get to know the Walton family?
  541. 22:07Um
  542. 22:15I can't remember the first introduction.
  543. 22:17I think my first contact with them was
  544. 22:19with Greg Penner,
  545. 22:20um who's the the chairman at Walmart. I
  546. 22:24I don't know who introduced me to him.
  547. 22:27He He was certainly one of the families
  548. 22:29that as we brainstormed on who were the
  549. 22:32the types of people that would want to
  550. 22:33be part of taking something like this on
  551. 22:36um that that we thought about.
  552. 22:40When you're
  553. 22:41I think you just said he was one of the
  554. 22:43people. So, do you mean um
  555. 22:45the Walton family or do you mean
  556. 22:46Walmart?
  557. 22:48Well, I What I was referring to was was
  558. 22:50it the Walton family is one of the the
  559. 22:52great, you know,
  560. 22:53sort of family controlled businesses
  561. 22:55that's been built in this country. Um
  562. 22:58we absolutely were also interested in
  563. 23:00the relationship with Walmart. Um and
  564. 23:03was that was early on part of our
  565. 23:04discussions with with Greg.
  566. 23:07Part of your discussions with Greg were
  567. 23:09to potentially partner with Walmart in
  568. 23:11the retail pharmacy space?
  569. 23:13Yes.
  570. 23:15And specifically I think he wanted them
  571. 23:17to evaluate the promise of this.
  572. 23:19Did you ever enter into a contract with
  573. 23:21Walmart?
  574. 23:22I don't think so.
  575. 23:23Did you have any other business
  576. 23:24relationship with them aside from having
  577. 23:26these discussions?
  578. 23:29Prior to meeting Greg, we'd had
  579. 23:32a fair amount of interaction with them.
  580. 23:34There was no formal contract about how
  581. 23:37you would
  582. 23:38roll out the concept was
  583. 23:40$4 lab testing like they'd done $4
  584. 23:43pharmacy prescriptions.
  585. 23:46And did anything come of that? Did you
  586. 23:48end up
  587. 23:50either piloting or rolling out any
  588. 23:52services even if you didn't have a
  589. 23:53contract?
  590. 23:54No, we were prohibited under the terms
  591. 23:56of our Walgreens and Safeway contracts
  592. 23:58initially from doing that for some
  593. 24:00period of time.
  594. 24:02I
  595. 24:03Did Greg Penner introduce you to Alice
  596. 24:05Walton?
  597. 24:06Or did someone else introduce you to
  598. 24:08him?
  599. 24:09Um
  600. 24:11I I believe
  601. 24:12was the point person for Alice. I I met
  602. 24:15Alice
  603. 24:16um
  604. 24:18at a dinner
  605. 24:19separately. I think she was sitting near
  606. 24:22me. Um
  607. 24:24Um
  608. 24:27But but I know
  609. 24:28um works with her.
  610. 24:31Do you ever meet Rob Walton?
  611. 24:33I did.
  612. 24:33What what what do you recall about that?
  613. 24:36Um
  614. 24:37I
  615. 24:39recall talking to him about this concept
  616. 24:42of $4 lab testing and the vision for
  617. 24:44what we were trying to do
  618. 24:46in the lab space in terms of access to
  619. 24:50health information.
  620. 24:51I recall telling him about
  621. 24:55the technology we were working to
  622. 24:57implement
  623. 24:58and I recall initially focusing on
  624. 25:01you know, what this could be if we did
  625. 25:03have the opportunity at some point to
  626. 25:05partner with Walmart and I mean then
  627. 25:07later he became an investor. He's Greg's
  628. 25:10father-in-law.
  629. 25:12How did he become an investor?
  630. 25:16Um
  631. 25:17so the
  632. 25:18what what vehicle or
  633. 25:20you know, is he on the list or was there
  634. 25:22an entity invested through?
  635. 25:24Yes, um the Madrone entity is is him and
  636. 25:28Greg and um
  637. 25:31the associated fund partners.
  638. 25:37So, um in looking through exhibit 196,
  639. 25:41we actually noticed that Rupert Murdoch
  640. 25:43doesn't appear on here.
  641. 25:46Um do you know why?
  642. 25:48Is he an investor?
  643. 25:51Or was he an investor in Theranos?
  644. 25:54He was an investor in Theranos, yes.
  645. 25:56So
  646. 25:58was he taken out? Is he still an
  647. 26:00investor in Theranos today?
  648. 26:02He is not.
  649. 26:03Is that the reason why he doesn't appear
  650. 26:05on this list?
  651. 26:06I don't know why he doesn't appear on
  652. 26:07this list.
  653. 26:08Do you know who prepares um you know,
  654. 26:10the capitalization table for Theranos?
  655. 26:13Or who maintains it?
  656. 26:14Um it's it's changed over time. It used
  657. 26:17to, I think now it's done by by one of
  658. 26:19our legal firms.
  659. 26:21Okay. But in the uh 2013-2014 time frame
  660. 26:25it would have you would have maintained
  661. 26:26it.
  662. 26:26I I believe so, yes.
  663. 26:30Um so, were you involved in discussions
  664. 26:32with um the investors in the C1 and C2
  665. 26:35round to invest in Theranos?
  666. 26:37I was.
  667. 26:38What was your involvement?
  668. 26:40Um I would talk about the kind of
  669. 26:43company we were trying to build, talk
  670. 26:45about the vision, talk about um why we
  671. 26:49were interested in structuring this as a
  672. 26:51private company and sort of the
  673. 26:52long-term nature of it and
  674. 26:55um what we thought we have the potential
  675. 26:58to do here.
  676. 27:00Were you involved in providing
  677. 27:02uh materials to them for their due
  678. 27:04diligence purposes?
  679. 27:07Um I I was involved.
  680. 27:10I
  681. 27:11just so I answer the question correctly,
  682. 27:13what what do you mean by that?
  683. 27:14So, were were you aware that these
  684. 27:16investors would sometimes request uh
  685. 27:19materials or documents from Theranos?
  686. 27:21Yes.
  687. 27:22And were you involved in compiling that
  688. 27:24information or collecting that
  689. 27:25information for them?
  690. 27:27I I don't know if I specifically did
  691. 27:29that, but I knew that the materials were
  692. 27:32going to investors.
  693. 27:34Okay. Would you review those materials
  694. 27:36or documents before they were sent to
  695. 27:37investors?
  696. 27:40You know, I I I would need to
  697. 27:43think about a specific instance to
  698. 27:46be able to speak about it specifically.
  699. 27:47I I certainly
  700. 27:49was generally aware of the the types of
  701. 27:51content that we were sending to
  702. 27:53investors.
  703. 27:54What what were the types of content that
  704. 27:55you were sending to investors?
  705. 27:58I mean, we we had a very
  706. 28:01um informal process in place, which was
  707. 28:04um
  708. 28:06you know, decks that we used for a
  709. 28:08number of different purposes in terms of
  710. 28:09slides we would share. They had data on
  711. 28:12the performance of our chemistries.
  712. 28:14Um
  713. 28:15we would share other information that we
  714. 28:18thought just gave people a perspective
  715. 28:20of
  716. 28:21what we were trying to do.
  717. 28:23Okay.
  718. 28:23Um it was it was
  719. 28:26it was a startup, so we didn't have the
  720. 28:28the systems in place to do this in a in
  721. 28:30a formal way.
  722. 28:32Uh did you would you sometimes be the
  723. 28:34person sending the materials to
  724. 28:36investors?
  725. 28:38Either through email or
  726. 28:40I I could have been. I I don't I can't
  727. 28:42sit here and say I remember a specific
  728. 28:44instance in which I did, but it it
  729. 28:46wouldn't surprise me if I did.
  730. 28:48What was Sunny Balwani's role in those
  731. 28:51discussions with investors?
  732. 28:54Um I would generally do the the first
  733. 28:57meeting or two and talk about the vision
  734. 28:59and then he would follow up on
  735. 29:01any questions that they had from a
  736. 29:02diligence perspective and
  737. 29:04um provide them with that information.
  738. 29:07Did he attend those initial meetings
  739. 29:09that you had with investors?
  740. 29:11Most of the time, yes.
  741. 29:13Did he participate in those
  742. 29:15meetings? Was he Would he be presenting
  743. 29:17material as well or was it mostly just
  744. 29:19you talking?
  745. 29:21The meetings that I was in which were
  746. 29:23sort of the initial meetings um
  747. 29:25we didn't frequently present anything.
  748. 29:27It was just discussion and and yes, he
  749. 29:28would be involved in the discussion as
  750. 29:30well.
  751. 29:31Was there anyone else from the company
  752. 29:32who was involved in those investor
  753. 29:34discussions besides you and Mr. Balwani?
  754. 29:37I I'm sure there were others in the room
  755. 29:39for certain meetings. I would I would
  756. 29:41need to think about a a specific meeting
  757. 29:43to be able to talk about who else was in
  758. 29:45there.
  759. 29:45Okay. Would there be others who would
  760. 29:47um
  761. 29:48be making a presentation to investors
  762. 29:51during those meetings? So I'm I'm more
  763. 29:53interested in the people who would have
  764. 29:54been
  765. 29:55speaking at those meetings. Can you
  766. 29:57think of anyone who would have besides
  767. 29:59you and Mr. Balwani who would have been
  768. 30:01speaking at those meetings?
  769. 30:02I mean if you could if you give me a
  770. 30:03specific meeting, I could I could try to
  771. 30:05think back to it. There was there was a
  772. 30:06lot of meetings over a period of many
  773. 30:08years. Um
  774. 30:10we had people to
  775. 30:13we were generally
  776. 30:15tried to respond to any questions that
  777. 30:17an investor had. So if they wanted to
  778. 30:19focus on a specific area, we might have
  779. 30:21had people who were specific to that
  780. 30:24area engage, but I I can't sit here and
  781. 30:27recall a
  782. 30:28specific example.
  783. 30:30Were there particular areas that uh you
  784. 30:33would present on and particular areas
  785. 30:35that Mr. Balwani would present on and
  786. 30:37what were those areas?
  787. 30:39Yeah, I I presented the vision, right?
  788. 30:41What we're trying to build, what we've
  789. 30:42invented, and what we think it could do.
  790. 30:44Yeah, um
  791. 30:45Sunny would present on our projections
  792. 30:49and what we thought it could mean
  793. 30:50financially and on the operations of the
  794. 30:53business, whether it be on manufacturing
  795. 30:56or the clinical lab.
  796. 30:59Uh when you were sitting in meetings
  797. 31:00with Mr. Balwani um and you're having
  798. 31:03these discussions with investors, were
  799. 31:04there times when
  800. 31:06um Mr. Balwani would present something
  801. 31:08to investors that you thought was not
  802. 31:10right or inaccurate?
  803. 31:14I don't I don't remember
  804. 31:17an instance in which that ever happened.
  805. 31:19I
  806. 31:20I I generally understood
  807. 31:23um
  808. 31:25at least what it what I saw to be the
  809. 31:26assumptions behind how he he
  810. 31:28characterized our potential.
  811. 31:31So, when you say you saw the assumptions
  812. 31:33behind how he would characterize your
  813. 31:35potential, what what did what do you
  814. 31:36mean by that?
  815. 31:38I mean, our our projections were
  816. 31:39generally based on an assumption that we
  817. 31:41would have a certain retail footprint
  818. 31:43and I knew that we had the ability to
  819. 31:46get that footprint if we executed and
  820. 31:49so I assumed that those numbers made
  821. 31:51sense in that context.
  822. 31:54So, you would you would have reviewed
  823. 31:55the assumptions before Mr. Balwani
  824. 31:58uh was presenting these financials to
  825. 32:00investors.
  826. 32:01Not not necessarily. Um I'm I'm sure
  827. 32:04sometimes I I did, but I um
  828. 32:07I'm not as a necessary normal operating
  829. 32:10cadence.
  830. 32:12But, you can't think of an instance in
  831. 32:13which Mr. Balwani would have presented,
  832. 32:15for instance, the financials to
  833. 32:16investors um that you thought was
  834. 32:19incorrect or inaccurate?
  835. 32:22You're talking about the projections?
  836. 32:23I'm talking about the financial
  837. 32:25projections now, yes.
  838. 32:27Not not at that time, no.
  839. 32:30Can you think of any instance in which
  840. 32:32um Mr. Balwani made any other inaccurate
  841. 32:35or incorrect statements to investors uh
  842. 32:37setting aside the financial projections?
  843. 32:42I mean, not not when I was in the room.
  844. 32:45That I can remember.
  845. 32:47Had he made an inaccurate or incorrect
  846. 32:49statement to investors, would you have
  847. 32:51corrected him?
  848. 32:52Absolutely.
  849. 32:54Um and were there times when Mr. Balwani
  850. 32:57corrected you while you were making your
  851. 32:58presentation to investors?
  852. 33:02I mean, he was not shy about jumping in
  853. 33:04on things that I would say. So, um
  854. 33:07he he was definitely very vocal in in
  855. 33:09those meetings.
  856. 33:14Was there ever a topic um
  857. 33:17in those discussions with investors in
  858. 33:18which you felt like you were
  859. 33:21not sufficiently familiar with it um and
  860. 33:24and so couldn't speak to it?
  861. 33:27Me personally?
  862. 33:28Yes.
  863. 33:28For sure.
  864. 33:29What what were those topics?
  865. 33:32I mean, this is why I deferred to other
  866. 33:33people on
  867. 33:36the operations of our clinical lab, on
  868. 33:38our operational infrastructure
  869. 33:40internally in terms of production, on
  870. 33:43financials and financial modeling. I
  871. 33:45didn't have any training or background
  872. 33:47in that.
  873. 33:48Were there any other areas?
  874. 33:51I'm sure there were. I mean, I'm
  875. 33:54I'm
  876. 33:56I'm
  877. 33:57I tried to be good in a couple of
  878. 33:59things, which generally have to do with
  879. 34:01inventing and sort of ideas and vision.
  880. 34:04I
  881. 34:05I
  882. 34:06I tried to surround myself with people
  883. 34:08who I thought were better than I was in
  884. 34:11in other areas.
  885. 34:13What about
  886. 34:14the product development area? Were you
  887. 34:16sufficiently familiar with that area to
  888. 34:18be able to speak to investors about it?
  889. 34:21In so far as the architecture of our
  890. 34:23technology, like the the idea of, for
  891. 34:26example, putting a robot in a
  892. 34:27distributed testing system, yes.
  893. 34:30Um in so far as
  894. 34:32how to interpret the data or the
  895. 34:34standards, I relied on on our teams.
  896. 34:38Okay. And so I think you said two things
  897. 34:41in terms of the data and what standards
  898. 34:43should be applied, you relied on your
  899. 34:45teams. So who was in charge of those two
  900. 34:47things at the company?
  901. 34:49So it depended on what data and what
  902. 34:52standards.
  903. 34:53From the perspective of R&D, it was our
  904. 34:57development or product leads who were
  905. 34:59the different team leads that
  906. 35:01were in place at different points in
  907. 35:02time. From the perspective of our
  908. 35:04clinical lab, it would
  909. 35:05So in the 2013 time frame that would
  910. 35:07have been are you talking about Was
  911. 35:09there another person that you mentioned
  912. 35:11earlier?
  913. 35:12Yeah, I'm trying to go back and remember
  914. 35:14who the team leads were in 2013 cuz it
  915. 35:17it evolved and we were generally trying
  916. 35:19to promote these scientists from within.
  917. 35:22I'm
  918. 35:23But yes, those are the types of people
  919. 35:25who
  920. 35:27would
  921. 35:29ensure that the assays were developed to
  922. 35:31the standards that we thought we were
  923. 35:34developing them to.
  924. 35:36Okay.
  925. 35:36Um
  926. 35:37And then you said the lab director for
  927. 35:39the clinical lab. So was that then in
  928. 35:41the 2013 time frame?
  929. 35:43time, yes.
  930. 35:44Okay.
  931. 35:45Um
  932. 35:46Would you
  933. 35:48be kept apprised of
  934. 35:51um what assays have been developed
  935. 35:54over the course of time? Was that
  936. 35:56something that you would be apprised of?
  937. 35:58It it was, yes. And we had sort of
  938. 36:00tracking spreadsheets at different
  939. 36:02periods of time to see, okay, how many
  940. 36:04assays have sort of hit these different
  941. 36:06steps that we thought were required to
  942. 36:09develop and validate the assays.
  943. 36:11Okay. Um and then would you also be kept
  944. 36:13apprised of how many of those have been
  945. 36:15transferred onto the hardware, onto the
  946. 36:17devices, the analyzers that would be
  947. 36:19analyzing the blood samples?
  948. 36:23I don't know that we ever tracked it
  949. 36:25like that.
  950. 36:26Um
  951. 36:27we always thought about it as you're
  952. 36:29you're de-
  953. 36:30developing chemistries that could work
  954. 36:32on small samples. And with these
  955. 36:34standardized tube types, you didn't need
  956. 36:36all the different color tubes.
  957. 36:38Um
  958. 36:39and then you could put them on two
  959. 36:40different hardware platforms. And that
  960. 36:43ultimately became a business decision
  961. 36:45around the business model that we
  962. 36:48decided to go with.
  963. 36:50So, you just said that you didn't really
  964. 36:51think about that too much. But why
  965. 36:53wasn't that important to the process?
  966. 36:56You know, actually putting the assays
  967. 36:57onto the machine because the machine is
  968. 36:59the
  969. 37:00the device that would actually be
  970. 37:01conducting the the testing.
  971. 37:03Um well, you you first need to know what
  972. 37:06your deployment is, right? So, if you're
  973. 37:08trying to deploy for a pharmaceutical
  974. 37:11clinical trial and you're trying to put
  975. 37:13machines in a distributed setting, then
  976. 37:15getting those assays validated on those
  977. 37:18machines makes sense.
  978. 37:20Um
  979. 37:20and during that period of time, we were
  980. 37:23mostly trying to develop a wide assay
  981. 37:26menu to show that
  982. 37:28this belief we had that any of these
  983. 37:30chemistries could be made to work with
  984. 37:32small samples was possible. And so, that
  985. 37:34was our our primary focus. And then when
  986. 37:37it became time to go into the clinical
  987. 37:39lab, we focused on putting them onto the
  988. 37:42specific hardware platforms that um we
  989. 37:45decided to put them on.
  990. 37:47So, were you kept apprised as to So, you
  991. 37:49said at some point um it was important
  992. 37:51to to actually validate the test.
  993. 37:54Yes.
  994. 37:54But were you apprised of that process
  995. 37:55and how many tests have been validated
  996. 37:57on the platforms?
  997. 38:02I think generally
  998. 38:04um yes. Um
  999. 38:07It just uh in terms of like the total
  1000. 38:09number of tests that we were working to
  1001. 38:11bring up in the lab initially is what
  1002. 38:13I'm I'm thinking about.
  1003. 38:17So, generally you were apprised of the
  1004. 38:19number of tests that were validated on
  1005. 38:21each of the platforms?
  1006. 38:23I I don't think I knew specifically how
  1007. 38:25many were on each platform. I knew
  1008. 38:29for example, when we launched that
  1009. 38:30generally we were working to bring up a
  1010. 38:32menu of 70 tests on finger stick and we
  1011. 38:34thought that would cover the ordering
  1012. 38:36patterns we were going to see. I knew
  1013. 38:37that there was, you know, certain
  1014. 38:39general numbers on different platforms,
  1015. 38:41but it wasn't like, okay, today, you
  1016. 38:43know, something came up on this platform
  1017. 38:45and I was alerted to that.
  1018. 38:54Okay, and were there any areas, going
  1019. 38:56back to my question about areas that you
  1020. 38:58weren't familiar with to speak with
  1021. 39:00investors about? Were there any areas
  1022. 39:02that
  1023. 39:03um
  1024. 39:04you had an understanding Mr. Balwani
  1025. 39:06wouldn't felt familiar with or
  1026. 39:08comfortable talking to investors about?
  1027. 39:11No.
  1028. 39:14So, he would have been familiar with all
  1029. 39:15aspects of the company, including for
  1030. 39:17instance, the vision and the mission of
  1031. 39:19the company as well?
  1032. 39:21Yeah, I mean, he's he's very confident
  1033. 39:23and he was confident that he was
  1034. 39:28able to
  1035. 39:30fill the role that he was in and
  1036. 39:32um supplement the knowledge that he
  1037. 39:35needed with other people.
  1038. 39:50So, um
  1039. 39:52you can put that aside now.
  1040. 39:55So,
  1041. 39:56I want to
  1042. 39:57go back to
  1043. 39:59um
  1044. 40:03the 20 10 time period for the time
  1045. 40:06being.
  1046. 40:07Um and I want to start by asking sort of
  1047. 40:11series of questions, but um
  1048. 40:14you know, if I use the word analyzers,
  1049. 40:15would you understand that that's what I
  1050. 40:17mean is the device that's used to
  1051. 40:18process blood tests?
  1052. 40:22Yeah, I'd then ask you which
  1053. 40:24which
  1054. 40:24Which analyzer? Okay. So, I think we'll
  1055. 40:26go through and um it would be helpful if
  1056. 40:28if you could actually um explain what
  1057. 40:31the different devices are and and the
  1058. 40:33versions and
  1059. 40:34um if I'm not being sufficiently clear,
  1060. 40:36uh please let me know if I'm not being
  1061. 40:37clear.
  1062. 40:38Sure.
  1063. 40:39Um so, in the 2010 time period, had
  1064. 40:45I think you mentioned previously there
  1065. 40:46were two devices that had been uh
  1066. 40:50developed and that were in use. There
  1067. 40:52was the 3.5
  1068. 40:54MiniLab and the four-series MiniLab. Do
  1069. 40:58you remember that testimony earlier?
  1070. 41:00Yes.
  1071. 41:00Okay.
  1072. 41:01And just to be clear, that's referring
  1073. 41:03to
  1074. 41:05what I'm sort of generally referring to
  1075. 41:06as this MiniLab family or the devices
  1076. 41:09that were intended to be distributed.
  1077. 41:11Okay.
  1078. 41:12Um
  1079. 41:16So,
  1080. 41:19and then you mentioned there was also a
  1081. 41:203.0, but that was similar to the 3.5
  1082. 41:23version.
  1083. 41:24Yes.
  1084. 41:24But um but we're not sure as to
  1085. 41:28what the difference
  1086. 41:29the differences are between those two
  1087. 41:31versions.
  1088. 41:32Do you have any understanding?
  1089. 41:34know specifically.
  1090. 41:35Okay.
  1091. 41:36Um
  1092. 41:37So, starting with 3.5 machine, was that
  1093. 41:40the machine that you believed would be
  1094. 41:43used for clinical testing
  1095. 41:45or was ready for clinical testing at
  1096. 41:46that time?
  1097. 41:48In 2010, we're talking about
  1098. 41:50Yeah, I'm just talking about 2010.
  1099. 41:52Um
  1100. 41:54used for clinical What do you mean by
  1101. 41:56used for clinical testing?
  1102. 41:57Um
  1103. 41:58well,
  1104. 41:59you know,
  1105. 42:00in 2010, were you
  1106. 42:02thinking about getting into a
  1107. 42:03relationship um with Walgreens and
  1108. 42:06Safeway and thinking about rolling this
  1109. 42:07out to retail pharmacy partners?
  1110. 42:09We were.
  1111. 42:10Okay. So, that's a clinical testing that
  1112. 42:12I'm thinking of. So, uh
  1113. 42:15um what kind of clinic what kind of
  1114. 42:18Well, let me step back. So, the 3.5
  1115. 42:20version, was that the version that you
  1116. 42:22were um thinking would be used for
  1117. 42:24clinical testing purposes at the retail
  1118. 42:26pharmacies?
  1119. 42:28At that time we believed it could be.
  1120. 42:30Okay. You believed it could be. What do
  1121. 42:32you mean by that?
  1122. 42:34What what I understood as of that period
  1123. 42:37of time is that the standards that were
  1124. 42:39required to satisfy the assay criteria
  1125. 42:43for a pharma trial
  1126. 42:45were the FDA standards, I thought, and
  1127. 42:48the FDA standards that meant you your
  1128. 42:51data was good enough for clinical
  1129. 42:52decision making. So,
  1130. 42:54we believed that the exact process that
  1131. 42:57we'd gone through for validating the
  1132. 42:58assays there would allow it to be used
  1133. 43:01in a clinical setting. We knew you would
  1134. 43:02need to get the CLIA waiver and
  1135. 43:05regulatory approval from the FDA.
  1136. 43:07Okay.
  1137. 43:08I'm sorry. So, you said you knew that
  1138. 43:10you needed to get approval from the FDA.
  1139. 43:12Yes.
  1140. 43:13Before using it for clinical testing.
  1141. 43:15Yes.
  1142. 43:15This was back in 2010.
  1143. 43:16setting.
  1144. 43:17In a distributed setting. So, what do
  1145. 43:19you mean by distributed setting?
  1146. 43:21Outside of a certified clinical lab.
  1147. 43:23Okay. And we're talking about 2010.
  1148. 43:25Is that right?
  1149. 43:27I I think so.
  1150. 43:28Okay.
  1151. 43:29I think so.
  1152. 43:30Um and then you mentioned that your
  1153. 43:31understanding as to how the machines
  1154. 43:33needed to be validated was how they were
  1155. 43:36validated for the
  1156. 43:39uh clinical trials you were doing for
  1157. 43:40pharmaceutical companies.
  1158. 43:42Yes.
  1159. 43:43How the tests were, yes.
  1160. 43:44Okay. So,
  1161. 43:45what was that validation process that
  1162. 43:47you undertook
  1163. 43:48for the pharmaceutical companies?
  1164. 43:50Um there's it my understanding was that
  1165. 43:52there's an FDA guidance document on a a
  1166. 43:55series of steps. There's like 15 steps
  1167. 43:58on sensitivity and specificity and other
  1168. 44:01measurements um that ensure that the
  1169. 44:04data
  1170. 44:06is good enough to be used for clinical
  1171. 44:09decision-making and at that time we
  1172. 44:11thought that was
  1173. 44:13what was in our development reports and
  1174. 44:14what was going to be required for
  1175. 44:17uh FDA submission.
  1176. 44:20Okay. Um and who was in charge of the
  1177. 44:22process of validating the devices to
  1178. 44:24make them ready for clinical testing?
  1179. 44:28Who was overseeing that process?
  1180. 44:30Um in 2010?
  1181. 44:32In 2010.
  1182. 44:34Um
  1183. 44:37I I don't know. We We always think about
  1184. 44:39it in terms of tests, uh not devices,
  1185. 44:42and it I I I again defer to
  1186. 44:45um whoever was leading the assay
  1187. 44:48initiatives at that time. Um
  1188. 44:51Who was leading the assay initiatives?
  1189. 44:53I I I can't remember in 2010. I don't
  1190. 44:55know.
  1191. 44:57Who would know who was in charge of that
  1192. 44:59process?
  1193. 45:01I I'm sure we can look back and and tell
  1194. 45:03you. I I don't I don't know if Sunny
  1195. 45:05would remember. Um
  1196. 45:07I
  1197. 45:08um
  1198. 45:11We We could talk to some of our other
  1199. 45:12scientists internally.
  1200. 45:14Okay.
  1201. 45:15And then uh on that version 3.5 minilab
  1202. 45:19Yes.
  1203. 45:19I think you mentioned uh previously
  1204. 45:21earlier in testimony that that version
  1205. 45:24could conduct You said tens of tests.
  1206. 45:28I think so.
  1207. 45:29Okay. What um and I think we we talked
  1208. 45:32about how that was something less than
  1209. 45:34100.
  1210. 45:35Yes.
  1211. 45:35What types of tests could it conduct?
  1212. 45:38So that version of device was focused on
  1213. 45:40a a method called immunochemistry um and
  1214. 45:43it was running those
  1215. 45:46types of tests for I I believe small
  1216. 45:48molecules, proteins, um
  1217. 45:53maybe metabolites, um
  1218. 45:56and antibodies. I'm not completely sure.
  1219. 45:59Um
  1220. 46:00Um
  1221. 46:03So what about and then I guess we talked
  1222. 46:06a little bit about the 4 series as well,
  1223. 46:07the 4 series mini lab. So, um I think
  1224. 46:10you mentioned that that was in
  1225. 46:11development and there were different
  1226. 46:13sectors that were being developed in the
  1227. 46:15machine. Do you remember that
  1228. 46:16discussion?
  1229. 46:17So, what was being done with the 4
  1230. 46:19series mini lab?
  1231. 46:22So, so the core
  1232. 46:24of our invention
  1233. 46:25was the concept of taking a robot
  1234. 46:28that could replicate what a human does
  1235. 46:31and putting it into a small box that
  1236. 46:34could be used outside of a lab.
  1237. 46:37The 3 series
  1238. 46:39detected the signals from the
  1239. 46:42chemistries
  1240. 46:44through one form of detection called
  1241. 46:47luminescence, which is measuring light,
  1242. 46:50measuring photons.
  1243. 46:51And what we wanted to do was add
  1244. 46:54other
  1245. 46:56detectors or capability of um other
  1246. 47:00light forms like fluorescence. Um so, we
  1247. 47:02were mounting other detectors around it
  1248. 47:05and that's what the 4 series is.
  1249. 47:07Okay. So, what could the 4 series test
  1250. 47:10in terms of um like what were the
  1251. 47:12numbers of tests that the 4 series could
  1252. 47:14perform at that time?
  1253. 47:16I I don't know. I
  1254. 47:18I think we
  1255. 47:21I I I'd be I'd be guessing.
  1256. 47:24Yeah.
  1257. 47:24Could it perform any number of tests?
  1258. 47:27We had essentially and we my my memory
  1259. 47:29is we had essentially shown
  1260. 47:32proof of concept of the ability to do
  1261. 47:35what I just said. I I don't know
  1262. 47:40um how many chemistries we'd actually
  1263. 47:42put on it um at that time.
  1264. 47:49Yes. So,
  1265. 47:50just to understand the the adding the
  1266. 47:52additional
  1267. 47:54set uh, let's say the fluorescence
  1268. 47:56capability, Would Would that enable the
  1269. 47:59uh, 4 series to to conduct tests in
  1270. 48:02theory beyond the immunochemistry
  1271. 48:05set?
  1272. 48:06Is it Is that Is that a fair
  1273. 48:07understanding?
  1274. 48:08Yes, and most importantly,
  1275. 48:11we were trying to invent a
  1276. 48:13a a platform
  1277. 48:15that could do
  1278. 48:17you know, the the objective was anything
  1279. 48:19that a lab could do. So, we needed the
  1280. 48:22full range of
  1281. 48:24options that are in a lab, so that if a
  1282. 48:26test came along that we hadn't tried to
  1283. 48:30develop yet, we had a box that could do
  1284. 48:33it, right? Architecturally.
  1285. 48:35And I mean, just broadly, what what kind
  1286. 48:37of tests are immunochemistry tests?
  1287. 48:40Um,
  1288. 48:41so those are the ones I was talking
  1289. 48:42about, proteins, antibodies, small
  1290. 48:44molecules, drug levels, um, could be
  1291. 48:47metabolites, um, essentially anything
  1292. 48:49that you bind to with an antibody.
  1293. 48:52And then, what were sort of
  1294. 48:54other than the category of
  1295. 48:55immunochemistry tests, what were the
  1296. 48:56other kind of categories of tests that
  1297. 48:58were sort of in that universe that you
  1298. 48:59wanted to have the architecture for for
  1299. 49:014 series?
  1300. 49:01Yeah, and so just to be clear,
  1301. 49:02immunochemistry is a method, right? It's
  1302. 49:04not a category of tests. There's many
  1303. 49:06different types of tests that can be
  1304. 49:08done with the method of immunochemistry.
  1305. 49:11Um,
  1306. 49:12we wanted to
  1307. 49:15um, we wanted to be able to do
  1308. 49:19essentially a broad range of methods,
  1309. 49:22right? So, we wanted to have a
  1310. 49:25what's called a microscopy microscopy
  1311. 49:27method for for imaging of cells. Um, we
  1312. 49:30wanted to
  1313. 49:32um,
  1314. 49:35have um,
  1315. 49:37fluorescence
  1316. 49:39as a readout for measuring um,
  1317. 49:43RNA and DNA for for pathogen detection.
  1318. 49:46Um,
  1319. 49:47and I I can list the other detectors
  1320. 49:49that were in there and what they're for,
  1321. 49:50if it's useful.
  1322. 49:51Sure, that'd
  1323. 49:53be great.
  1324. 49:53Okay. So,
  1325. 49:55um
  1326. 49:57imaging, fluorescence, microscopy,
  1327. 50:00um
  1328. 50:02we we still had the luminescence
  1329. 50:04capability,
  1330. 50:06uh and absorbance.
  1331. 50:08So, it's essentially the full range of
  1332. 50:10readouts. What we're trying to do is
  1333. 50:11take the lab and put it in a box.
  1334. 50:18Did you have to use that phrase when
  1335. 50:20when talking to other people, lab in a
  1336. 50:22box?
  1337. 50:25I'm I wouldn't be surprised if I did. I
  1338. 50:27I can't sit here and say I remember
  1339. 50:29specific conversation. Yeah,
  1340. 50:31we most often talked about the concept
  1341. 50:33of mini lab, which was miniaturized
  1342. 50:35laboratory.
  1343. 50:38Um
  1344. 50:39so, I want to skip forward then to a few
  1345. 50:41years later now, and we're talking again
  1346. 50:43about 2013. So,
  1347. 50:46tell us what devices Theranos had
  1348. 50:49developed to process blood tests at that
  1349. 50:51time.
  1350. 50:54So, when the clinical lab went live,
  1351. 50:58um
  1352. 50:59which I believe was in
  1353. 51:01um
  1354. 51:03I I I think we did our our first sort of
  1355. 51:06official patient testing around the end
  1356. 51:07of October 2013.
  1357. 51:10The date is probably not exact. Um
  1358. 51:13we
  1359. 51:14had both our
  1360. 51:173.5 mini lab devices, as well as
  1361. 51:21what we called at that time
  1362. 51:23high-throughput
  1363. 51:25platforms, which are open systems that
  1364. 51:28you can put your proprietary protocols
  1365. 51:32on
  1366. 51:33to run small sample testing.
  1367. 51:36And so, those included a number of
  1368. 51:38different devices, one of which was the
  1369. 51:41Advia 1800. Um
  1370. 51:43there was a a
  1371. 51:45cytometry one that was made by Beckton
  1372. 51:47Beckton Dickinson and I believe there
  1373. 51:49was a couple others.
  1374. 51:51Okay, so just going back so you said
  1375. 51:53there was the TSPU
  1376. 51:54Mhm.
  1377. 51:55um or the mini lab. What are we calling
  1378. 51:57it at this time?
  1379. 51:59At that time we were calling it the
  1380. 52:01TSPU.
  1381. 52:02Okay, so there was the TSPU, which
  1382. 52:04version was it?
  1383. 52:05I I believe that was the 3.5 version.
  1384. 52:07It's still the 3.5 version. Okay, and
  1385. 52:10how many tests could be run on the 3.5?
  1386. 52:14Do you mean how many were run in the
  1387. 52:15clinical lab or could be run?
  1388. 52:17Uh I mean how many were validated to be
  1389. 52:20run for clinical testing?
  1390. 52:22Um I believe that
  1391. 52:25we brought up about 15 in the clinical
  1392. 52:27lab at that time.
  1393. 52:29About 15?
  1394. 52:30Yes.
  1395. 52:31Okay, and what what time frame in 2013
  1396. 52:33are you referring to when you say about
  1397. 52:3515?
  1398. 52:37Um I so I
  1399. 52:38Are you thinking about before the launch
  1400. 52:40of Theranos services in Walgreens?
  1401. 52:43Um I was thinking of sort of the initial
  1402. 52:45launch of the services in Walgreens. So
  1403. 52:47it was um
  1404. 52:49when the lab
  1405. 52:50formally started seeing patients through
  1406. 52:53to the next few months. Let's say 3 to 4
  1407. 52:56months after. I'm not I don't know
  1408. 52:57exactly when the tests were validated in
  1409. 52:59that range.
  1410. 53:00Okay.
  1411. 53:00So you think about 15 tests were
  1412. 53:02validated on the TSPU 3.5.
  1413. 53:06Um and then you mentioned there were
  1414. 53:08other open platforms including the Avia
  1415. 53:111800, um some machine that was
  1416. 53:13manufactured by What was it? Beckman?
  1417. 53:16Yes.
  1418. 53:17Um what's the name of the company?
  1419. 53:19Not the Avia, but there was another one
  1420. 53:21that was manufactured by Beckman
  1421. 53:22Coulter.
  1422. 53:23Coulter, okay. Um
  1423. 53:25So what did what did Theranos do to
  1424. 53:27those machines to
  1425. 53:28It could have been Becton Dickinson. I'm
  1426. 53:30sorry. I'm not sure, one of the two.
  1427. 53:32Okay.
  1428. 53:32One. Yeah.
  1429. 53:33Um
  1430. 53:34so what what had Theranos done to those
  1431. 53:37open platform machines in order to
  1432. 53:40um
  1433. 53:42uh make it capable for these machines to
  1434. 53:44be processing tests on smaller samples.
  1435. 53:48Yeah, so different um modifications for
  1436. 53:52different platforms.
  1437. 53:53Um speaking about the Advia
  1438. 53:56specifically,
  1439. 53:57we had um taken our protocol, which is
  1440. 54:02essentially our formula for how to make
  1441. 54:04the chemistry work with the small
  1442. 54:06volume,
  1443. 54:07and
  1444. 54:08as I understand it,
  1445. 54:10overtaken essentially the the the
  1446. 54:13software in the instrument to implement
  1447. 54:15our protocol.
  1448. 54:17Um and then we modified the physical
  1449. 54:22hardware. There's little
  1450. 54:23cups that are used to contain the
  1451. 54:25sample, and one of the reasons that
  1452. 54:27people take so much blood in blood
  1453. 54:29testing is that those cups have a lot of
  1454. 54:32loss. So, even though you only take out
  1455. 54:35a tiny amount,
  1456. 54:36you have to leave behind a lot of loss
  1457. 54:38in the cup, and so we we changed the
  1458. 54:41geometry so that you didn't have that
  1459. 54:43loss, and
  1460. 54:46then on other open platforms, like for
  1461. 54:49the cells, it was our
  1462. 54:51uh chemistries that were run on them,
  1463. 54:54too. So, we actually made like the
  1464. 54:57antibody in the chemistry that binded to
  1465. 54:59the cell that lit up um to go into the
  1466. 55:02assay.
  1467. 55:02Okay. So,
  1468. 55:04uh the Advia 1800, there is you
  1469. 55:07mentioned a couple other machines that
  1470. 55:08were made by another company. These were
  1471. 55:10These were all uh
  1472. 55:12machines that weren't manufactured by
  1473. 55:14Theranos. Is that right?
  1474. 55:17Correct. We purchased the machines and
  1475. 55:19then we modified the hardware.
  1476. 55:21We modified the hardware. So, um So, we
  1477. 55:24might be talking about this a lot uh
  1478. 55:26during today. So, if I said um if I
  1479. 55:28refer to these machines as, you know,
  1480. 55:30third-party commercially available
  1481. 55:32machines, um would you understand that
  1482. 55:35I'm talking about the Advia 1800,
  1483. 55:37anything that with Theranos did not had
  1484. 55:40not manufactured. Would you understand
  1485. 55:42that?
  1486. 55:43So, I
  1487. 55:43I think it's important to distinguish
  1488. 55:45that there were were also actual
  1489. 55:46third-party commercial machines that
  1490. 55:48were not modified that were in the
  1491. 55:50laboratory as well. Okay. So, we had we
  1492. 55:52had both platforms that we were doing
  1493. 55:55hardware modifications as well as
  1494. 55:57unmodified commercial machines.
  1495. 55:59Okay. So, it sounds like there were
  1496. 56:01three categories of of machines then,
  1497. 56:03right? There is the TSPU 3.5 version
  1498. 56:07that Theranos had manufactured. Is that
  1499. 56:09right? And then there was the
  1500. 56:12some third-party commercially available
  1501. 56:14machines that Theranos had modified.
  1502. 56:16Correct.
  1503. 56:17And then there were also just other
  1504. 56:18third-party
  1505. 56:20commercially available machines that
  1506. 56:22Theranos had purchased in order to
  1507. 56:24conduct testing. Would that be via
  1508. 56:26venous draw?
  1509. 56:28Um yes.
  1510. 56:29So, these machines would be conducting
  1511. 56:31testing in in sort of the traditional
  1512. 56:33venipuncture way.
  1513. 56:35Yes, and I believe there was also a
  1514. 56:37couple of
  1515. 56:39um
  1516. 56:40point-of-care devices that were in the
  1517. 56:42lab like
  1518. 56:43I don't think it was a glucose meter but
  1519. 56:45kind of like a glucose meter.
  1520. 56:47Um but they were commercial unmodified.
  1521. 56:48You just wouldn't be putting venous
  1522. 56:49blood on them.
  1523. 56:51Does that make sense?
  1524. 56:52Okay. Um I think I understand that.
  1525. 56:55Can I ask for just a clarification on
  1526. 56:56the um
  1527. 56:57the um
  1528. 57:00the hardware modified
  1529. 57:01commercially available devices or that
  1530. 57:03second category that that she just
  1531. 57:05referenced.
  1532. 57:05Yes.
  1533. 57:06And you mentioned the hardware
  1534. 57:07modification was I I guess that the
  1535. 57:09modifications were sort of the software
  1536. 57:11programming that the the machine and
  1537. 57:13then the
  1538. 57:14the geometry of the cup.
  1539. 57:16Is that is that
  1540. 57:17fair?
  1541. 57:17Yes, and and on other instruments it was
  1542. 57:22it was also our what I sometimes call
  1543. 57:23chemistry, which is essentially we did
  1544. 57:26the work to make
  1545. 57:28the antibody or the binder and then we
  1546. 57:30made all the other reagents like for the
  1547. 57:33cytometry assays and then put them on
  1548. 57:36these platforms that could then run our
  1549. 57:39our tests.
  1550. 57:40It
  1551. 57:42you know earlier we sort of talked about
  1552. 57:43the the idea of you know the consumable
  1553. 57:45being
  1554. 57:46you know what was put in the device. Is
  1555. 57:49the is the is the modified geometry to
  1556. 57:53lack of a better word on my part. Is
  1557. 57:55that sort of also a consumable for for
  1558. 57:58that platform?
  1559. 57:59It is. I was speaking specifically to
  1560. 58:02the conversation about the TSPU and what
  1561. 58:06a consumable was to it but
  1562. 58:08there's consumables there and there's
  1563. 58:10other consumables like the nanotainers.
  1564. 58:12And and is it is it would you consider
  1565. 58:14the time a reagent to be a consumable as
  1566. 58:17well?
  1567. 58:18No. Okay.
  1568. 58:20I don't think so. I mean I wouldn't now.
  1569. 58:24So we've been going about an hour. Can
  1570. 58:25we take another break? Short break?
  1571. 58:27Sure.
  1572. 58:28We're off the record at
  1573. 58:2911:30.
  1574. 58:40We are back on the record at 11:46.
  1575. 58:43Ms. Holmes, did you have any substantive
  1576. 58:45conversations with the SEC staff during
  1577. 58:47break?
  1578. 58:48I did not.
  1579. 58:50So we were talking about modifying some
  1580. 58:52of these third-party commercially
  1581. 58:54available machines in order to test
  1582. 58:57smaller samples before we left on the
  1583. 58:59break. When was when were these machines
  1584. 59:02modified?
  1585. 59:06So I believe the
  1586. 59:10the way the way I think about it is the
  1587. 59:12implementation of our protocols onto
  1588. 59:14them happened in 2013 before the
  1589. 59:19clinical lab went live I I think.
  1590. 59:22And why did Theranos have to develop
  1591. 59:25these modified protocols
  1592. 59:27uh during that time period?
  1593. 59:30Um well, I'm just to be clear, the the
  1594. 59:33protocols themselves date back to our
  1595. 59:36original inventions in like 2005. Yeah,
  1596. 59:39and the reason that we had to
  1597. 59:42implement them on those
  1598. 59:45open platforms was because
  1599. 59:48we needed to process large numbers of
  1600. 59:51samples in a centralized lab environment
  1601. 59:54as opposed to the
  1602. 59:55the TSPUs are designed to be near
  1603. 59:58patient and process one sample at a
  1604. 1:00:01time, and I think it takes
  1605. 1:00:02like 30 minutes to an hour per sample,
  1606. 1:00:05and we needed to be able to run a lot of
  1607. 1:00:07samples at the same time in a
  1608. 1:00:10centralized setting. So, that was why we
  1609. 1:00:12were trying to figure out how to do this
  1610. 1:00:14in a high-throughput way.
  1611. 1:00:16So, the TSPU could only process one
  1612. 1:00:18sample at a time?
  1613. 1:00:19That's right.
  1614. 1:00:20Okay. And you mentioned it How long
  1615. 1:00:23would it take to process that sample?
  1616. 1:00:25It It depends on the chemistry. It could
  1617. 1:00:27be anywhere from
  1618. 1:00:2818 minutes to an hour.
  1619. 1:00:32Um and I think you mentioned uh
  1620. 1:00:34It It could be different times, too. I
  1621. 1:00:35mean, it varied per test.
  1622. 1:00:37Okay.
  1623. 1:00:38Um you mentioned before we took the
  1624. 1:00:40break uh at the time in 2013 when you
  1625. 1:00:43were getting ready to launch Theranos's
  1626. 1:00:45services
  1627. 1:00:47um through Walgreens that the TSPU
  1628. 1:00:50was validated to run about 15 tests. Do
  1629. 1:00:54you remember that earlier testimony?
  1630. 1:00:57Um I I do, and and again, forgive me. I
  1631. 1:01:00I think there were
  1632. 1:01:0115 tests in the clinical lab that were
  1633. 1:01:03validated on the TSPU, if that makes
  1634. 1:01:06sense. Um
  1635. 1:01:07Okay. What What was What was the
  1636. 1:01:09distinction between what I was saying
  1637. 1:01:10and what you were saying?
  1638. 1:01:11Yeah. Yeah, sorry. Um
  1639. 1:01:13the way that I think about it is that
  1640. 1:01:15um
  1641. 1:01:16the the TSPU itself
  1642. 1:01:18we had thought at that time was
  1643. 1:01:20validated to run a lot of tests, which
  1644. 1:01:23you know, at one point we got up to
  1645. 1:01:25about three over 300 chemistries that we
  1646. 1:01:28developed and many of them, like 90 or
  1647. 1:01:31so, I think were actually on the TSPU.
  1648. 1:01:3415, we had validated as laboratory
  1649. 1:01:37developed tests in the clinical lab as
  1650. 1:01:40of that time, I believe.
  1651. 1:01:42Okay, so just so that I'm clear and I
  1652. 1:01:44understand what you're saying. So,
  1653. 1:01:46you're saying there were about 300 or so
  1654. 1:01:49that
  1655. 1:01:50the TSPU was
  1656. 1:01:52or that Theranos had developed assays
  1657. 1:01:55for, right?
  1658. 1:01:56Um about something I think we had talked
  1659. 1:02:00about in 2010, something like less than
  1660. 1:02:02100 were
  1661. 1:02:04um
  1662. 1:02:07Maybe you should explain it again
  1663. 1:02:09because I'm not really understanding
  1664. 1:02:10what the difference is between
  1665. 1:02:12what was what was validated in 2010 and
  1666. 1:02:14what was validated in 2013.
  1667. 1:02:16Yeah, so so by the end of 2013, I
  1668. 1:02:20believe that from a
  1669. 1:02:22an R&D standpoint, about 90 or so
  1670. 1:02:27uh
  1671. 1:02:28tests had been
  1672. 1:02:30we thought validated at that time on the
  1673. 1:02:33TSPU.
  1674. 1:02:34A subset of those
  1675. 1:02:37went live in the clinical lab on the
  1676. 1:02:40TSPU. I believe that was about 15
  1677. 1:02:43around 2013.
  1678. 1:02:46There were also other chemistries that
  1679. 1:02:49we had developed that were running on
  1680. 1:02:51other platforms beside the TSPU.
  1681. 1:02:54Does that make sense?
  1682. 1:02:55Okay, so 90 tests were validated to run
  1683. 1:02:57on the TSPU in 2013.
  1684. 1:03:00I believe so. About 90.
  1685. 1:03:03Okay, but only 15 were being run in the
  1686. 1:03:05clinical lab.
  1687. 1:03:07Yes.
  1688. 1:03:07Why weren't you running the other
  1689. 1:03:11remaining tests
  1690. 1:03:13out of the 90?
  1691. 1:03:14We put
  1692. 1:03:16Well, out of the 90
  1693. 1:03:18Why weren't you running the other 75
  1694. 1:03:20tests on the TSPU?
  1695. 1:03:22So, the reasons changed over time.
  1696. 1:03:24Around 2013, I think we were initially
  1697. 1:03:27working to bring up in the clinical lab
  1698. 1:03:30setting additional tests on the TSPU.
  1699. 1:03:33And then at some point in time, we
  1700. 1:03:34stopped and focused on the modified
  1701. 1:03:38platforms as well as just trying to get
  1702. 1:03:40those tests through the FDA
  1703. 1:03:43so that they could be used in the phase
  1704. 1:03:45two setting.
  1705. 1:03:47Uh
  1706. 1:03:48So, different the business model evolved
  1707. 1:03:51and the strategy evolved.
  1708. 1:03:53Okay. So, even though you had 90 tests
  1709. 1:03:55validated on the TSPU, you decided only
  1710. 1:03:58to run 15 on the TSPU because
  1711. 1:04:03you had to get approval for the tests.
  1712. 1:04:06And you you decided to
  1713. 1:04:09uh focus more on the modified
  1714. 1:04:12um protocol with the third-party
  1715. 1:04:14commercially available machines.
  1716. 1:04:16Yeah, so just um
  1717. 1:04:18on that point, there were I believe
  1718. 1:04:21about 90 development and validation
  1719. 1:04:23reports with tests on the TSPU. Um
  1720. 1:04:28the
  1721. 1:04:29um
  1722. 1:04:30the remainder
  1723. 1:04:33we had done through
  1724. 1:04:35uh other platforms. The subset of those
  1725. 1:04:39went live in the clinical lab on the
  1726. 1:04:40TSPU. Um the remainder of the focus in
  1727. 1:04:44the clinical lab, as I understand it,
  1728. 1:04:47was on the the systems that could
  1729. 1:04:49process a lot of samples at the same
  1730. 1:04:50time.
  1731. 1:04:53I I I think there was some work to get
  1732. 1:04:55more than 15 up. Um but I know that that
  1733. 1:04:58work stopped and I I don't know when.
  1734. 1:05:02You mentioned sort of the distinction
  1735. 1:05:04between the the 15 tests that were
  1736. 1:05:08ready to go as as LDTs versus the 90
  1737. 1:05:10that were
  1738. 1:05:11uh
  1739. 1:05:12that were validated on the platform.
  1740. 1:05:15In your mind, what was the difference
  1741. 1:05:16between
  1742. 1:05:18uh having a test be an LDT versus it
  1743. 1:05:21being validated for the platform, I
  1744. 1:05:23guess?
  1745. 1:05:24Yeah.
  1746. 1:05:24What what's the difference between the
  1747. 1:05:25two?
  1748. 1:05:26Sure. So, so when I use the words
  1749. 1:05:28validated for the platform, I was
  1750. 1:05:30referring to our understanding of the
  1751. 1:05:33development guidelines that were
  1752. 1:05:34required for these tests, namely the FDA
  1753. 1:05:38assay development reference.
  1754. 1:05:40The clinical lab had its own separate
  1755. 1:05:43validation process for any tests that
  1756. 1:05:46went live. And so, there were separate
  1757. 1:05:48activities that were underway for each
  1758. 1:05:51of those 15 prior to the lab director
  1759. 1:05:54signing off on them.
  1760. 1:05:56And did you have an understanding at the
  1761. 1:05:57time about substantively what that
  1762. 1:05:59meant? I mean,
  1763. 1:06:01um in terms of I mean,
  1764. 1:06:03what the folks in the lab were doing to
  1765. 1:06:05No, I I knew that they had a separate
  1766. 1:06:08validation process. I don't I I didn't
  1767. 1:06:11know what the differences between the
  1768. 1:06:12two were in in a substantive way.
  1769. 1:06:20So, it sounds like there were two
  1770. 1:06:23different kinds of validation processes
  1771. 1:06:25that were
  1772. 1:06:26um
  1773. 1:06:27being performed on the TSP. The first
  1774. 1:06:30was, according to what you said, the FDA
  1775. 1:06:33guidelines.
  1776. 1:06:35I think, you know, in in retrospect,
  1777. 1:06:37it's what we had interpreted to be
  1778. 1:06:41FDA's guidance document for assay
  1779. 1:06:43development. And so, when I use the
  1780. 1:06:45words developed and validated, that's
  1781. 1:06:46what I'm referring to.
  1782. 1:06:48Okay. But, you mentioned before um there
  1783. 1:06:50were some characteristics of that
  1784. 1:06:52validation process, including, you know,
  1785. 1:06:54certain measures like
  1786. 1:06:56test specificity and
  1787. 1:06:58um precision and some of these other
  1788. 1:07:01categories. That was what your
  1789. 1:07:02understanding was with respect to
  1790. 1:07:05um how to validate the device under the
  1791. 1:07:08FDA guidelines.
  1792. 1:07:11Yes, those are elements of that process
  1793. 1:07:14and then there were certain criteria
  1794. 1:07:16that were acceptable um
  1795. 1:07:19for each of those sets of experiments
  1796. 1:07:22that we had used that guidance document
  1797. 1:07:25as an indicator of making sure that we
  1798. 1:07:27were
  1799. 1:07:28as good as we had wanted to be.
  1800. 1:07:30Okay. And then, um, you mentioned there
  1801. 1:07:33was a separate validation procedure that
  1802. 1:07:35the CLIA lab was doing.
  1803. 1:07:38Is that right?
  1804. 1:07:39Okay. And and so
  1805. 1:07:41as of 2013, only 15 tests had been
  1806. 1:07:45validated under the CLIA procedure.
  1807. 1:07:48Correct.
  1808. 1:07:49On the TSPU.
  1809. 1:07:50Yes.
  1810. 1:07:51I I think.
  1811. 1:07:52But you're
  1812. 1:07:53But you have no understanding as to what
  1813. 1:07:55that CLIA procedure for validation is.
  1814. 1:07:59My My understanding is that it's
  1815. 1:08:01similar, but that there's some parts
  1816. 1:08:03that are different and that
  1817. 1:08:05it's specific to
  1818. 1:08:08um
  1819. 1:08:11uh essentially what the lab director
  1820. 1:08:14determines are the acceptance criteria
  1821. 1:08:16for a lab-developed test. I I don't know
  1822. 1:08:19specifically what aspects were differing
  1823. 1:08:21from our our own development and
  1824. 1:08:23validation of the assays.
  1825. 1:08:26Okay. And then, going back to then the
  1826. 1:08:29third-party commercially available
  1827. 1:08:31machines that uh Theranos had modified
  1828. 1:08:35uh how many tests could those machines
  1829. 1:08:38perform?
  1830. 1:08:40And just so I answer the question best,
  1831. 1:08:42um
  1832. 1:08:44could they perform meaning how many LDTs
  1833. 1:08:47had we validated in the clinical lab on
  1834. 1:08:48them?
  1835. 1:08:49Yes.
  1836. 1:08:49Um I I believe there was
  1837. 1:08:53um about 60 or so. Um I'm I'm not sure
  1838. 1:08:56what the exact number was.
  1839. 1:08:59Okay, so about 15 were validated, um,
  1840. 1:09:02pursuant to the clear procedure on the
  1841. 1:09:04TSPU at that time, and 60 were on the
  1842. 1:09:07modified commercially available
  1843. 1:09:09machines.
  1844. 1:09:10Yes.
  1845. 1:09:10Okay. And then
  1846. 1:09:12Just to be clear, those numbers are not
  1847. 1:09:13exact, but it's about those numbers. I
  1848. 1:09:16don't know the exact numbers.
  1849. 1:09:18Okay. But in terms of the number, you
  1850. 1:09:20think it would be something less than
  1851. 1:09:21100 on the modified machines?
  1852. 1:09:23I do.
  1853. 1:09:24Okay. And then in terms of the third
  1854. 1:09:26category of machines, which would have
  1855. 1:09:28been just the regular third-party
  1856. 1:09:31commercially available machines that
  1857. 1:09:32were running Venus blood.
  1858. 1:09:34Mhm.
  1859. 1:09:34Um how many tests could those that those
  1860. 1:09:37machines perform?
  1861. 1:09:39Would Would it just be the remainder of
  1862. 1:09:40the tests that Theranos is offering?
  1863. 1:09:43Um well, we ran the remainder either on
  1864. 1:09:45those or by sending out to the reference
  1865. 1:09:48labs.
  1866. 1:09:49Um and I don't know exactly how many
  1867. 1:09:51were on the the commercial machines.
  1868. 1:09:53Okay. But they would either be performed
  1869. 1:09:55on the third-party commercially
  1870. 1:09:56available machines or they would be sent
  1871. 1:09:58out to reference labs.
  1872. 1:09:58Correct. Yes.
  1873. 1:10:01Just a couple of clarifications there.
  1874. 1:10:02So, the the 15 or so that were on the
  1875. 1:10:05TSPU and the the 60 or so that were on
  1876. 1:10:07the modified commercially available, are
  1877. 1:10:10those mutually exclusive sets or is
  1878. 1:10:12there any overlap between
  1879. 1:10:14the LDTs on those platforms?
  1880. 1:10:16question. Um
  1881. 1:10:18I think the way we're counting them,
  1882. 1:10:20it's mutually exclusive. We We
  1883. 1:10:24So,
  1884. 1:10:25the open platforms were capable of
  1885. 1:10:28running a couple of the tests that we
  1886. 1:10:30put on the TSPU. I don't know whether we
  1887. 1:10:32ever ran them on both. I think for the
  1888. 1:10:34purpose of this discussion, it's okay to
  1889. 1:10:36consider them as different tests.
  1890. 1:10:40Um and then you sort of just thinking
  1891. 1:10:42thinking back through your answer about
  1892. 1:10:44the
  1893. 1:10:45you understood that there were 15 LDTs
  1894. 1:10:47that were that were on the TSPU. There
  1895. 1:10:49were there were about 90, again,
  1896. 1:10:52ballpark, that were validated in your in
  1897. 1:10:55the company's view with on the TSPU.
  1898. 1:10:58No. Oh, sorry. Yeah.
  1899. 1:10:59Um what was there
  1900. 1:11:01was there ever a situation where uh
  1901. 1:11:04someone at the company told you that
  1902. 1:11:05additional LDTs weren't being brought
  1903. 1:11:08onto the
  1904. 1:11:09TSPU because of
  1905. 1:11:11challenges in in uh
  1906. 1:11:13in getting those
  1907. 1:11:15you know, one of those 90 validated
  1908. 1:11:18to the Theranos understanding
  1909. 1:11:20tests up to the LDT standard.
  1910. 1:11:25I
  1911. 1:11:27So, I can't remember any specific
  1912. 1:11:28conversations. I I knew that there were
  1913. 1:11:32ongoing
  1914. 1:11:33sort of initiatives and and challenges
  1915. 1:11:35in general in bringing LDTs up, but I
  1916. 1:11:38thought that
  1917. 1:11:40the fact that our lab director had
  1918. 1:11:41signed off on the reports for the first
  1919. 1:11:4315 meant that there were no fundamental
  1920. 1:11:47issues in the ability to bring up more
  1921. 1:11:50tests, and um certainly believed that uh
  1922. 1:11:54you know, as we worked to then take
  1923. 1:11:56those
  1924. 1:11:58um same tests that we'd done the
  1925. 1:12:00development on
  1926. 1:12:01into the pre-submission process for FDA.
  1927. 1:12:53I'm handing to you what's been marked
  1928. 1:12:55there as Exhibit 197.
  1929. 1:13:05Is that 3419?
  1930. 1:13:09Exhibit 197
  1931. 1:13:13purports to be a June 11th, 2013 email
  1932. 1:13:18from Sunny Balwani to Elizabeth Holmes.
  1933. 1:13:21The subject line is forward demo next
  1934. 1:13:23Tuesday, 6/11 at noon with starting
  1935. 1:13:27Bates number ATS-0902539.
  1936. 1:13:32Have you seen Exhibit 197 before?
  1937. 1:13:37I don't know. I I don't remember it. Um
  1938. 1:13:40I'm not sure.
  1939. 1:13:44Is this your email address at Theranos,
  1940. 1:13:46[email protected]?
  1941. 1:13:48It is.
  1942. 1:13:48Do you have any reason to believe that
  1943. 1:13:50you might not have received this?
  1944. 1:13:51I don't.
  1945. 1:13:53Uh what is this email about?
  1946. 1:13:57Do you mind if I take just a second to
  1947. 1:13:59read this?
  1948. 1:14:43It looks like it's an exchange on
  1949. 1:14:46um
  1950. 1:14:49trying to do a a demonstration of
  1951. 1:14:52one of the mini lab devices.
  1952. 1:14:54Okay.
  1953. 1:14:55Um and do you recall who that
  1954. 1:14:57demonstration was for?
  1955. 1:14:58No.
  1956. 1:15:00So, if you look at the initial email on
  1957. 1:15:02the bottom of um
  1958. 1:15:04the the second page, which is 540,
  1959. 1:15:08he's writing to uh Do you have that
  1960. 1:15:10email?
  1961. 1:15:11I do.
  1962. 1:15:12Uh and he states or he writes, rather,
  1963. 1:15:14"Sunny mentioned that he'd like to run a
  1964. 1:15:16demo during an exec meeting next
  1965. 1:15:18Tuesday. It runs from 12:00 to p.m. in
  1966. 1:15:20our office here."
  1967. 1:15:22Do you
  1968. 1:15:23know what he's referring to when he says
  1969. 1:15:24exec meeting?
  1970. 1:15:26I don't.
  1971. 1:15:27Is exec short for executive?
  1972. 1:15:29I I'm assuming so, yes.
  1973. 1:15:31And did you have executive meetings at
  1974. 1:15:33Theranos?
  1975. 1:15:36Leslie, I'm not quite sure what is an
  1976. 1:15:38what an executive meeting is. Um
  1977. 1:15:41I I currently hold executive team
  1978. 1:15:43meetings. I I don't think that's what
  1979. 1:15:45this is referring to.
  1980. 1:15:46Okay. Do you think it might be referring
  1981. 1:15:48to a meeting with
  1982. 1:15:50a business partner
  1983. 1:15:52or someone from the outside?
  1984. 1:15:54I I'd be guessing. I have no idea.
  1985. 1:15:56So,
  1986. 1:16:02So, if you then flip to the first page
  1987. 1:16:05at 539,
  1988. 1:16:07you'll see that um
  1989. 1:16:10as they're setting up this
  1990. 1:16:11demonstration, he's then writing on June
  1991. 1:16:1310th
  1992. 1:16:15to
  1993. 1:16:16um a number of individuals at the
  1994. 1:16:18company, including and he's copying
  1995. 1:16:19Sunny Balwani at the bottom. He says,
  1996. 1:16:21"For tomorrow's demo as listed below,
  1997. 1:16:22we'd like to have a mini lab in either a
  1998. 1:16:254S or Monobay
  1999. 1:16:27uh with the Normandy shell uploaded,
  2000. 1:16:29whichever works better." So, he's
  2001. 1:16:31mentioning a number of different um
  2002. 1:16:33devices. Uh
  2003. 1:16:35there's the 4S and the Monobay.
  2004. 1:16:38Do you know what he's talking about
  2005. 1:16:40here?
  2006. 1:16:43So, I'm I'm not sure specifically. I
  2007. 1:16:46think
  2008. 1:16:48just looking at the chain here in the
  2009. 1:16:49reference to mobile labs up above that
  2010. 1:16:52he's distinguishing 4S as the
  2011. 1:16:56device that we'd been investing in
  2012. 1:16:59uh for
  2013. 1:17:00the DoD deployments that we had wanted
  2014. 1:17:02to do
  2015. 1:17:03uh and the mono bay as uh the version of
  2016. 1:17:06it which
  2017. 1:17:07we later began to think about as the
  2018. 1:17:10uh um the mini lab that could be used at
  2019. 1:17:13at retail or physician offices.
  2020. 1:17:15What was the difference between the 4S
  2021. 1:17:17and the mono bay?
  2022. 1:17:18The 4S was designed to be much more
  2023. 1:17:20compact and to try to um be developed to
  2024. 1:17:24some of the standards that were set by
  2025. 1:17:26special operations command for things
  2026. 1:17:29that could be lifted and transported uh
  2027. 1:17:32in
  2028. 1:17:33a way that their command could handle
  2029. 1:17:35and it also had a lot of investment in
  2030. 1:17:37things like vibration mounts
  2031. 1:17:39um to make it more robust for use in
  2032. 1:17:43more um
  2033. 1:17:46uh
  2034. 1:17:46difficult settings.
  2035. 1:17:48Okay. And then what and so how is the
  2036. 1:17:50mono bay different from that?
  2037. 1:17:52It was not intended to be used in
  2038. 1:17:56um
  2039. 1:17:57sort of more extreme environments. It
  2040. 1:17:59was designed for sort of a
  2041. 1:18:01routine
  2042. 1:18:02uh
  2043. 1:18:03clinical setting kind of like our
  2044. 1:18:05wellness centers.
  2045. 1:18:07Uh
  2046. 1:18:08so in other words, it was was it bigger
  2047. 1:18:11than than the 4S?
  2048. 1:18:13I think it was bigger, but it also it
  2049. 1:18:15just didn't have the same vibration
  2050. 1:18:17control and other things that would
  2051. 1:18:19ultimately be required if you were going
  2052. 1:18:21to do those types of
  2053. 1:18:22um deployments the DoD was interested
  2054. 1:18:25in.
  2055. 1:18:25Were there any differences in
  2056. 1:18:27capabilities between the two devices?
  2057. 1:18:31I don't know. I I there might have been.
  2058. 1:18:33I'm I'm I'm sure there was. I I don't
  2059. 1:18:35remember specifically what.
  2060. 1:18:38Uh
  2061. 1:18:39who would know the answer to that
  2062. 1:18:39question?
  2063. 1:18:42Um
  2064. 1:18:46I'm just looking at the email to
  2065. 1:18:52I don't know specifically. Um
  2066. 1:18:56the product teams that were working on
  2067. 1:18:57it at the time
  2068. 1:18:59who's listed here
  2069. 1:19:01um
  2070. 1:19:02I'm sure would have known what this was
  2071. 1:19:04referring to at the time.
  2072. 1:19:07Okay. And when mentions the Normandy
  2073. 1:19:10shell being uploaded onto the machine,
  2074. 1:19:12did you understand what he meant by
  2075. 1:19:13that?
  2076. 1:19:16I'm not completely sure what he means by
  2077. 1:19:18that. I
  2078. 1:19:20It's a It's a piece of software and I
  2079. 1:19:22don't
  2080. 1:19:24know why he wants to put that software
  2081. 1:19:26on it. It must have been for some type
  2082. 1:19:27of demonstration purposes.
  2083. 1:19:29What is the Normandy shell?
  2084. 1:19:32I don't know.
  2085. 1:19:33I'm not sure.
  2086. 1:19:35So, you just said it's a piece of
  2087. 1:19:36software. Did she know what the software
  2088. 1:19:38did?
  2089. 1:19:39I don't. I know that there was a
  2090. 1:19:40reference I know it's software because
  2091. 1:19:42it says Normandy shell and so that is
  2092. 1:19:44probably some type of shell software
  2093. 1:19:46system. I don't know
  2094. 1:19:48what code it refers to it.
  2095. 1:19:50It might be
  2096. 1:19:53a version of the software that allows
  2097. 1:19:54you to report results from the device,
  2098. 1:19:56but I'm I'm purely
  2099. 1:19:58guessing based on looking at the email
  2100. 1:20:00now.
  2101. 1:20:01What is Normandy?
  2102. 1:20:04Um Normandy is a word that was used to
  2103. 1:20:06refer to a number of different projects
  2104. 1:20:09internally in so far as I was familiar
  2105. 1:20:11with it. It referred to
  2106. 1:20:14the concept of having samples sent to a
  2107. 1:20:18central lab through the nanotainer in
  2108. 1:20:20phase one of our sort of business model.
  2109. 1:20:24Um and then later deploying the device.
  2110. 1:20:26I know Sunny used it in the software
  2111. 1:20:29setting and I think even in the lab
  2112. 1:20:31setting for a number of
  2113. 1:20:33different
  2114. 1:20:34uh purposes. I'm not quite sure exactly
  2115. 1:20:36all the use cases.
  2116. 1:20:40So, if you look at the response then
  2117. 1:20:42back from, which is just about email,
  2118. 1:20:45he says, "I've just finished getting the
  2119. 1:20:47device OS installed with Normandy app
  2120. 1:20:50and properly running the null protocol
  2121. 1:20:53on mobile labs for an eight."
  2122. 1:20:56So, what did you understand him to be
  2123. 1:20:57saying there?
  2124. 1:21:02Are you just sort of figuring out
  2125. 1:21:03whether I should to interpret the
  2126. 1:21:05document now, or you asking whether it
  2127. 1:21:07refreshes a recollection going back to
  2128. 1:21:09that time period?
  2129. 1:21:10I'm asking her what her I mean, it
  2130. 1:21:13sounds like she doesn't necessarily
  2131. 1:21:15recall this this email, but I'm asking
  2132. 1:21:18what her understanding is of what's
  2133. 1:21:19being written in this email now.
  2134. 1:21:22Yeah, I mean, looking at it now,
  2135. 1:21:24um
  2136. 1:21:27it says he's installed software on it.
  2137. 1:21:30And I I don't know what the null
  2138. 1:21:31protocol was. Um
  2139. 1:21:35and
  2140. 1:21:36I think that the mobile labs is a
  2141. 1:21:38reference to
  2142. 1:21:40the version of 4S at that time, but I'm
  2143. 1:21:42not sure.
  2144. 1:21:43So, you don't know what null protocol is
  2145. 1:21:45referring to?
  2146. 1:21:46I don't.
  2147. 1:21:47Have you ever heard that um
  2148. 1:21:50that phrase before?
  2149. 1:21:53I don't recognize it. I may have heard
  2150. 1:21:55it before. Um I'm not
  2151. 1:21:58I don't know what it is.
  2152. 1:21:59Okay.
  2153. 1:22:00Um
  2154. 1:22:00I I would guess it's a test protocol,
  2155. 1:22:01but I'm not sure.
  2156. 1:22:02What do you mean by test protocol?
  2157. 1:22:05A lot of times when you want to make
  2158. 1:22:06sure that the instrument is functioning
  2159. 1:22:08properly, you have a it's kind of like a
  2160. 1:22:10QC protocol or a a test protocol that
  2161. 1:22:13allows you to ensure that whatever
  2162. 1:22:16software you've installed or
  2163. 1:22:18um whatever configuration you've put the
  2164. 1:22:19device in, it it operates properly.
  2165. 1:22:22Okay. Did you ever conduct
  2166. 1:22:23demonstrations where um a blood sample
  2167. 1:22:26was actually put into a device and the
  2168. 1:22:29device, you know, tested the blood
  2169. 1:22:31sample.
  2170. 1:22:33Did you ever
  2171. 1:22:35conduct an a demonstration like that?
  2172. 1:22:37Yes.
  2173. 1:22:38When when did you do that?
  2174. 1:22:41Very frequently. I'm
  2175. 1:22:44and
  2176. 1:22:45many times over
  2177. 1:22:47all the years.
  2178. 1:22:48And
  2179. 1:22:49would you, you know, after putting the
  2180. 1:22:51blood sample into the device, would that
  2181. 1:22:53device then generate a result?
  2182. 1:22:57If we put a blood sample into it?
  2183. 1:22:59Yes.
  2184. 1:23:00If it was programmed to, yes.
  2185. 1:23:02And were there times where you generated
  2186. 1:23:04that result while, you know, whoever you
  2187. 1:23:06were conducting that demonstration for
  2188. 1:23:08was present?
  2189. 1:23:09Yes.
  2190. 1:23:10And who do you recall doing that for?
  2191. 1:23:14Well, I know we gave
  2192. 1:23:16one of the early versions of the mini
  2193. 1:23:17lab to Walgreens to keep at their
  2194. 1:23:20headquarters so that they could do that
  2195. 1:23:21themselves whenever they wanted. I'm
  2196. 1:23:26I I don't have specific
  2197. 1:23:29recollections of the meeting, but I I
  2198. 1:23:32believe we
  2199. 1:23:34I'm
  2200. 1:23:35brought devices to at least Safeway to
  2201. 1:23:38use in their conference room and run
  2202. 1:23:40samples on when we were first forming
  2203. 1:23:42that relationship. I'm I know
  2204. 1:23:46we would do it
  2205. 1:23:48I'm
  2206. 1:23:51we we've done it for I'm board members a
  2207. 1:23:54few times when whenever it was a
  2208. 1:23:56relevant part of talking about that part
  2209. 1:23:58of our our business model.
  2210. 1:24:01Do you ever recall instances where you
  2211. 1:24:05uh
  2212. 1:24:08where you instructed others at Theranos
  2213. 1:24:10to
  2214. 1:24:12um run a program on the devices so that
  2215. 1:24:15it would look like the machine was
  2216. 1:24:17running even though it wasn't actually
  2217. 1:24:19processing a test?
  2218. 1:24:22We have test protocols that essentially
  2219. 1:24:24allow you to show the device um
  2220. 1:24:27functioning. Um we
  2221. 1:24:30will do that in a lot, including for
  2222. 1:24:32open systems of the
  2223. 1:24:34open demonstrations of the device where
  2224. 1:24:36you want people to see the architecture.
  2225. 1:24:38Okay.
  2226. 1:24:38Um so it it runs essentially a
  2227. 1:24:42for lack of a better word, dummy
  2228. 1:24:42protocol. Um so that you can see how the
  2229. 1:24:46inside of the instrument moves or
  2230. 1:24:48see the user interface or those types of
  2231. 1:24:50things.
  2232. 1:24:51Right. So even if it's not processing a
  2233. 1:24:53test, you you would be able to see that
  2234. 1:24:54the machine is actually running inside.
  2235. 1:24:57Is that what a test protocol is for?
  2236. 1:24:59Either running inside or seeing how the
  2237. 1:25:01software GUI works on the outside.
  2238. 1:25:05Uh and do you recall using those test
  2239. 1:25:07protocols a lot during your
  2240. 1:25:09demonstrations?
  2241. 1:25:12I mean again, we would
  2242. 1:25:13do demonstrations in response to
  2243. 1:25:16questions or interest in certain parts
  2244. 1:25:18of the system. So
  2245. 1:25:21um
  2246. 1:25:22we do it a lot now because we show
  2247. 1:25:25open sort of versions of the device to
  2248. 1:25:27show people the architecture. I know we
  2249. 1:25:29did it at at certain points in time in
  2250. 1:25:32the past, depending on what the context
  2251. 1:25:34of the meeting was and what people were
  2252. 1:25:36interested in seeing about the device.
  2253. 1:25:39What Was there a name for So in those
  2254. 1:25:41instances in which you were actually
  2255. 1:25:43testing a blood sample and it's going
  2256. 1:25:45into machine, was there a name for the
  2257. 1:25:47program or the software that would be
  2258. 1:25:48uploaded to the machine in order to do
  2259. 1:25:50that?
  2260. 1:25:52I don't know.
  2261. 1:25:53I don't know.
  2262. 1:25:54Who would know the answer to that
  2263. 1:25:55question?
  2264. 1:25:57Name for the
  2265. 1:25:59the software to run the test protocol? I
  2266. 1:26:01I would say that
  2267. 1:26:02talking about uh the instance It's It
  2268. 1:26:03sounds like from what what I understand
  2269. 1:26:06what you've just been saying is that the
  2270. 1:26:08test protocol is something that can be
  2271. 1:26:09put on the machine to
  2272. 1:26:11to sort of mimic how the machine would
  2273. 1:26:14work if it was testing uh a sample, but
  2274. 1:26:17is there a separate program that would
  2275. 1:26:19be put on a machine in the case that
  2276. 1:26:21you're conducting an
  2277. 1:26:23a demonstration where you're actually
  2278. 1:26:24putting in a blood sample?
  2279. 1:26:28Um,
  2280. 1:26:29so if you're putting in a blood sample
  2281. 1:26:31and you're reporting a test result, then
  2282. 1:26:33the test result will be specific to
  2283. 1:26:36whatever chemistry is on that cartridge
  2284. 1:26:38and that's what's reported out
  2285. 1:26:41to the end user in the end.
  2286. 1:26:44If you're
  2287. 1:26:46I'm not I'm not quite sure.
  2288. 1:26:49So, maybe I don't understand how the
  2289. 1:26:51machines work. Are they already as a
  2290. 1:26:53default program to conduct tests on
  2291. 1:26:56blood samples? So, in other words, you
  2292. 1:26:59would put the blood sample in, the
  2293. 1:27:00machine would conduct the test, and the
  2294. 1:27:03test result would be generated?
  2295. 1:27:06Um, so the way that our
  2296. 1:27:09TSPU systems work is that on each
  2297. 1:27:11cartridge there's a barcode and that
  2298. 1:27:13barcode can be specific to a chemistry
  2299. 1:27:16that's loaded into the cartridge. It
  2300. 1:27:17could be specific to a test protocol,
  2301. 1:27:21like a QC protocol or if it was going to
  2302. 1:27:24go through the movements but not
  2303. 1:27:25actually run an actual chemistry.
  2304. 1:27:28And
  2305. 1:27:30um
  2306. 1:27:32anything else that you would want the
  2307. 1:27:33instrument to do. So, it would be
  2308. 1:27:34determined by whatever on the cartridge.
  2309. 1:27:37If that makes sense, whatever barcode is
  2310. 1:27:38on the cartridge.
  2311. 1:27:41So, the barcode on the cartridge
  2312. 1:27:43determines whether it's running one
  2313. 1:27:45protocol versus another?
  2314. 1:27:46Yes.
  2315. 1:27:48So, when you're talking about the test
  2316. 1:27:50protocol, it's is it not a software
  2317. 1:27:53that's being loaded onto the device?
  2318. 1:27:57I I'm not aware of soft So, there's an
  2319. 1:28:00operating system on the device. The
  2320. 1:28:02protocol
  2321. 1:28:04I believe the barcode calls a server and
  2322. 1:28:07then it determines what protocol to run
  2323. 1:28:10based on what's on the barcode.
  2324. 1:28:14Okay. Um then if you look back at the at
  2325. 1:28:17exhibit 197 then
  2326. 1:28:21um
  2327. 1:28:22responds uh that same day
  2328. 1:28:26and he says, "Right now we're not
  2329. 1:28:27planning to run anything on the mini
  2330. 1:28:30lab, unfortunately. Um the general
  2331. 1:28:33chemistry and ELISA assays are not
  2332. 1:28:36performing adequately for a demo at the
  2333. 1:28:38moment."
  2334. 1:28:39Um
  2335. 1:28:40so it
  2336. 1:28:41is that right? Is ML referring to the
  2337. 1:28:43mini lab?
  2338. 1:28:46I I think so given the references here
  2339. 1:28:49to mobile labs and mini lab. I'm not
  2340. 1:28:52quite sure exactly what it's referring
  2341. 1:28:53to, but it could be.
  2342. 1:28:55Okay. And so he's referring he's
  2343. 1:28:57actually responding back to Sunny
  2344. 1:28:58Balwani's question um about what you're
  2345. 1:29:01planning to run on the ML. Do you see
  2346. 1:29:03that?
  2347. 1:29:04I do.
  2348. 1:29:05Okay. Um so
  2349. 1:29:09it sounds like the general chemistry and
  2350. 1:29:11the ELISA assays were not performing um
  2351. 1:29:14or or
  2352. 1:29:16were not
  2353. 1:29:17I guess performing accurately or
  2354. 1:29:18adequately on the mini lab at that time.
  2355. 1:29:21Does that refresh your recollection that
  2356. 1:29:24the mini lab was not actually performing
  2357. 1:29:27assays in this timeframe?
  2358. 1:29:29It it doesn't. I mean there's there's a
  2359. 1:29:31lot of reasons why
  2360. 1:29:33they could have had issues with it. We
  2361. 1:29:35would
  2362. 1:29:35as you know been doing immunochemistries
  2363. 1:29:38for many years on
  2364. 1:29:40earlier versions of this platform.
  2365. 1:29:42Okay, but they're actually talking about
  2366. 1:29:44the 4S and the Monobay.
  2367. 1:29:47I don't
  2368. 1:29:47Was it So is it your understanding that
  2369. 1:29:49the 4S and the Monobay could conduct
  2370. 1:29:51testing?
  2371. 1:29:54Yes.
  2372. 1:29:56How many tests could We we had this
  2373. 1:29:58conversation earlier, but how many tests
  2374. 1:30:00could the 4S or the four series mini lab
  2375. 1:30:03perform?
  2376. 1:30:05My understanding was that we were going
  2377. 1:30:07through the process to take all of the
  2378. 1:30:09chemistries that we'd developed, the the
  2379. 1:30:11few hundred that we were talking about,
  2380. 1:30:13and put them onto the four
  2381. 1:30:17series platform. I don't know
  2382. 1:30:19which of these this is referring to and
  2383. 1:30:21begin the process of getting them into
  2384. 1:30:23the FDA later in 2013.
  2385. 1:30:26Okay. And so, was it your understanding
  2386. 1:30:28then that
  2387. 1:30:30those tests were validated on the
  2388. 1:30:32MiniLab 4S?
  2389. 1:30:35The development and validation work I
  2390. 1:30:36don't think was on the 4S device, but it
  2391. 1:30:38was my understanding that the validation
  2392. 1:30:40on the three series translated to the
  2393. 1:30:42four series. So, you would have to run
  2394. 1:30:45it again on the four series hardware,
  2395. 1:30:47but it was essentially the same
  2396. 1:30:48architecture of a a robot moving fluid
  2397. 1:30:51around now with more uh detectors for
  2398. 1:30:54different readouts.
  2399. 1:30:56So, I mean maybe I don't understand. So,
  2400. 1:30:58are
  2401. 1:31:01was the four was the MiniLab 4S
  2402. 1:31:04performing any tests in 2013? Was it
  2403. 1:31:07capable of performing any tests?
  2404. 1:31:10I thought it was. I mean I'm I'm saying
  2405. 1:31:13that just based on
  2406. 1:31:15remembering engaging with the FDA. We
  2407. 1:31:17brought it to the FDA and we
  2408. 1:31:19began the pre-submission process on it
  2409. 1:31:21with the FDA that year.
  2410. 1:31:23And had you validated those tests on the
  2411. 1:31:26MiniLab 4S?
  2412. 1:31:28Again, I think the the development and
  2413. 1:31:30validation reports were on earlier
  2414. 1:31:32iterations of the hardware, but we
  2415. 1:31:35um believed and I believed that you
  2416. 1:31:38could
  2417. 1:31:39basically take the same chemistry that's
  2418. 1:31:40been created and run it on this
  2419. 1:31:42iteration of the hardware. Just to be
  2420. 1:31:44clear, you said 4S. I'm speaking
  2421. 1:31:47generally about MiniLab. I don't know if
  2422. 1:31:49it was 4S or another version of the four
  2423. 1:31:52series platform.
  2424. 1:31:53Okay. Um I think probably we should
  2425. 1:31:56clarify that we're when we're talking
  2426. 1:31:57about the MiniLab, at least with With to
  2427. 1:32:00this email, we're talking about the four
  2428. 1:32:01series.
  2429. 1:32:02Yeah, exactly.
  2430. 1:32:03Okay.
  2431. 1:32:04Um okay, so you think that maybe during
  2432. 1:32:07this time frame there were some issues
  2433. 1:32:09with being able to adequately perform
  2434. 1:32:12the uh general chemistry or Eliza assays
  2435. 1:32:15on the Mini Lab 4S, but that generally
  2436. 1:32:17speaking
  2437. 1:32:19your understanding was that these
  2438. 1:32:20devices could conduct the test?
  2439. 1:32:23My understanding was that
  2440. 1:32:25architecturally what we had created with
  2441. 1:32:27the four series from a hardware
  2442. 1:32:29perspective
  2443. 1:32:30was sound and that all the chemistries
  2444. 1:32:33that we'd made over the years
  2445. 1:32:35could be put on it and taken through the
  2446. 1:32:38FDA as we later did with HSV which got
  2447. 1:32:42cleared. And I I certainly knew that
  2448. 1:32:45like with any
  2449. 1:32:47you know, new technology that was coming
  2450. 1:32:48up, there would be issues.
  2451. 1:32:50Um but
  2452. 1:32:51I I was never aware that there were any
  2453. 1:32:53showstoppers in being able to do that
  2454. 1:32:56with the four series platform.
  2455. 1:33:06Okay, you can put that one aside.
  2456. 1:33:41So, I'm going to hand to you
  2457. 1:33:44what's been marked there in this exhibit
  2458. 1:33:46198.
  2459. 1:33:54This is tab four.
  2460. 1:33:58Is that at 198? purports to be a January
  2461. 1:34:0123rd, 2014 email
  2462. 1:34:04from to Elizabeth Holmes with a copy to
  2463. 1:34:08a number of individuals. Starting Bates
  2464. 1:34:10number is TS-0469692.
  2465. 1:34:14Have you seen exhibit 198 before?
  2466. 1:34:19I I I recognize it. I I don't know if
  2467. 1:34:21I've seen it since sending it, but I
  2468. 1:34:23recognize it.
  2469. 1:34:25What is exhibit 198?
  2470. 1:34:27Um it's an email exchange between me and
  2471. 1:34:30with the FDA.
  2472. 1:34:34So, if you look at your initial email
  2473. 1:34:37um on January 22nd,
  2474. 1:34:402014, you're noting
  2475. 1:34:43in your email
  2476. 1:34:45um
  2477. 1:34:46I think you're getting ready to provide
  2478. 1:34:47a copy
  2479. 1:34:48of some updated plans for some
  2480. 1:34:51pre-submissions to the FDA. Do you see
  2481. 1:34:53that?
  2482. 1:34:55I'm sorry, where are you?
  2483. 1:34:56Uh your your email to
  2484. 1:34:58Okay.
  2485. 1:34:59Do you see that you're providing him
  2486. 1:35:00with a copy of an updated plan?
  2487. 1:35:02Yes.
  2488. 1:35:02That's in the first sentence of your
  2489. 1:35:03email.
  2490. 1:35:04Yes.
  2491. 1:35:04Uh you then say for your reference as of
  2492. 1:35:06now, uh vit D, is that short for vitamin
  2493. 1:35:09D?
  2494. 1:35:10Yes.
  2495. 1:35:11Uh TSH, PSA, and FT4 Eliza assays are
  2496. 1:35:16the only assays run through the Theranos
  2497. 1:35:18processing device in Theranos's CLEA lab
  2498. 1:35:21on patient samples collected at Theranos
  2499. 1:35:23wellness centers.
  2500. 1:35:24Was that consistent with your
  2501. 1:35:25understanding that uh
  2502. 1:35:28there were only four tests that were
  2503. 1:35:30being run on the Theranos uh
  2504. 1:35:34I guess the TSPU from patient samples
  2505. 1:35:36being obtained from the wellness
  2506. 1:35:39wellness centers at Walgreens?
  2507. 1:35:41I'm I'm sure it was at that time. We
  2508. 1:35:43were making sure to keep the FDA
  2509. 1:35:45completely apprised of everything we
  2510. 1:35:47were doing.
  2511. 1:35:49Okay.
  2512. 1:35:50Um do you know why only four of the
  2513. 1:35:52assays were being run on the TSP during
  2514. 1:35:54this time and this is January of 2014?
  2515. 1:35:58I I don't. If all 15 of them had been
  2516. 1:36:01brought up by then, then this is
  2517. 1:36:02probably just based on the orders we and
  2518. 1:36:05we also hadn't really seen that many
  2519. 1:36:07patients on fingerstick by this period
  2520. 1:36:08of time.
  2521. 1:36:13Do the um
  2522. 1:36:15was there a time when uh
  2523. 1:36:17the number of tests that were being
  2524. 1:36:19performed on the TSP changed? Was it
  2525. 1:36:22just a matter of bringing the the next
  2526. 1:36:25you know,
  2527. 1:36:26uh 11 or so tests online and having them
  2528. 1:36:29validated?
  2529. 1:36:32No. Um
  2530. 1:36:34we generally looked at this based on
  2531. 1:36:37ordering patterns and
  2532. 1:36:39our belief was and and still is that
  2533. 1:36:42about 70 assays will cover al- almost
  2534. 1:36:46100% of the orders that um you'll get
  2535. 1:36:50from the types of prac- physician
  2536. 1:36:52practices that we were trying to serve.
  2537. 1:36:54Um so
  2538. 1:36:56the goal was to match that test menu.
  2539. 1:37:00As I said earlier, I think there was a
  2540. 1:37:01period of time in which we thought more
  2541. 1:37:03than 15 would go up. I know that that
  2542. 1:37:05changed and I'm not sure exactly when it
  2543. 1:37:07changed, but um
  2544. 1:37:10we weren't necessarily just linearly
  2545. 1:37:12looking at bringing up more assays on an
  2546. 1:37:15ongoing basis.
  2547. 1:37:16Okay. So, what is your understanding as
  2548. 1:37:18to the maximum number of tests that the
  2549. 1:37:20TSP ever performed on patient samples
  2550. 1:37:23from Walgreens?
  2551. 1:37:24I I think it's that 15 number. Yeah.
  2552. 1:37:34You can put that one aside.
  2553. 1:37:44FlexSure.
  2554. 1:38:01I'm handing to you what's been marked
  2555. 1:38:03Theranos Exhibit 199.
  2556. 1:38:14So, is there a difference here that
  2557. 1:38:16binds two-sided and there's
  2558. 1:38:17Yes, that's That's why it looks a little
  2559. 1:38:18thicker.
  2560. 1:38:19Um
  2561. 1:38:21Exhibit 199 purports to be
  2562. 1:38:25Defendant Theranos Inc.'s
  2563. 1:38:28uh responses and objections to
  2564. 1:38:29Plaintiff's first set of interrogatories
  2565. 1:38:32that were filed uh in the Court of
  2566. 1:38:34Chancery of the State of Delaware in the
  2567. 1:38:37Partner Investments LP versus Theranos
  2568. 1:38:40Inc.
  2569. 1:38:42case.
  2570. 1:38:44Have you seen Exhibit 199 before?
  2571. 1:38:49I don't know.
  2572. 1:38:51I I might have.
  2573. 1:38:55Are you aware that there was a lawsuit
  2574. 1:38:57that was filed by Partner Investments
  2575. 1:38:59and uh PFM Healthcare Master Fund
  2576. 1:39:02against Theranos?
  2577. 1:39:03Yes.
  2578. 1:39:07Would you have been involved and were
  2579. 1:39:09you involved in preparing responses to
  2580. 1:39:11their um
  2581. 1:39:14uh interrogatories?
  2582. 1:39:16I certainly was engaged with our legal
  2583. 1:39:19team on
  2584. 1:39:20responding to them. I I don't know what
  2585. 1:39:22my specific role was in
  2586. 1:39:24responding to the interrogatories. I'm
  2587. 1:39:26sure I talked with our team about it.
  2588. 1:39:29I I may have seen some of the documents.
  2589. 1:39:30I I don't have a specific memory of
  2590. 1:39:33you know, what exact documents I looked
  2591. 1:39:34at sitting here.
  2592. 1:39:35Sure.
  2593. 1:39:36Um if you could just turn to
  2594. 1:39:39page with Bates number ending 3465.
  2595. 1:39:48And just for the record, the starting
  2596. 1:39:49Bates number on this document is
  2597. 1:39:51SEC-PRN-E-0003430.
  2598. 1:39:57So, are you on
  2599. 1:39:59uh 3465?
  2600. 1:40:01Yes.
  2601. 1:40:01Okay. So, here in interrogatory number
  2602. 1:40:0415, uh Theranos has submitted a response
  2603. 1:40:07and looks like PFM is asking the about
  2604. 1:40:12the number of um
  2605. 1:40:15blood tests that were being processed
  2606. 1:40:17through the TSPU beginning in January
  2607. 1:40:201st, 2013
  2608. 1:40:23for clinical uh patient testing. Do you
  2609. 1:40:25see the the response here?
  2610. 1:40:28I I do.
  2611. 1:40:28Okay. And Theranos response that there
  2612. 1:40:30are a number of tests that were being
  2613. 1:40:32performed on the TSPU and by my count,
  2614. 1:40:34there are about 12 of them.
  2615. 1:40:36Uh that start and those that list starts
  2616. 1:40:39in at 3465 and ends on 3466.
  2617. 1:40:44Yes.
  2618. 1:40:44You see that? Is that consistent with
  2619. 1:40:46your understanding of the tests that
  2620. 1:40:48were performed on the TSPU?
  2621. 1:40:55Um
  2622. 1:40:56yeah, and I I don't have any reason to
  2623. 1:40:58doubt this.
  2624. 1:41:00And
  2625. 1:41:00at looking at the list, were there any
  2626. 1:41:02other tests that you believed were being
  2627. 1:41:05tested or performed on the TSPU that
  2628. 1:41:08aren't being listed here?
  2629. 1:41:11You know, if there's 12 here, I had the
  2630. 1:41:12number 15 in my head. It may have been
  2631. 1:41:15that
  2632. 1:41:16either they weren't up by this period of
  2633. 1:41:18time or they were never run, they were
  2634. 1:41:20validated, or I could be wrong about the
  2635. 1:41:2115 number, I'm not sure.
  2636. 1:41:23Okay. So,
  2637. 1:41:24do you have any reason to believe that
  2638. 1:41:26um
  2639. 1:41:27only
  2640. 1:41:28otherwise, that only tests that only 12
  2641. 1:41:30tests were being performed on the TSPU?
  2642. 1:41:34I don't know. I if if that's what this
  2643. 1:41:37says, I don't have any reason to doubt
  2644. 1:41:38it.
  2645. 1:41:39Okay.
  2646. 1:41:40Did you ever share the fact that the
  2647. 1:41:42TSPU was um
  2648. 1:41:45only performing about 12 tests
  2649. 1:41:48with Walgreens?
  2650. 1:41:51I I don't
  2651. 1:41:54I don't think so. I don't know.
  2652. 1:41:58You're not aware of an instance in which
  2653. 1:42:00you might have told Walgreens that the
  2654. 1:42:01TSPU was only performing 12 tests?
  2655. 1:42:03I I'm not.
  2656. 1:42:07Are you aware of ever informing Safeway
  2657. 1:42:10that the TSPU was performing 12 tests in
  2658. 1:42:12this time frame, 2013?
  2659. 1:42:15I mean, after the Clear Lab went live, I
  2660. 1:42:17don't think we had any discussions with
  2661. 1:42:19them about
  2662. 1:42:21what we were doing in the clinical lab.
  2663. 1:42:24Did you ever uh share or did you ever
  2664. 1:42:27discuss the fact that the TSPU was
  2665. 1:42:29performing about 12 tests with Sunny
  2666. 1:42:31Balwani?
  2667. 1:42:34I I can't remember a specific discussion
  2668. 1:42:36about it. Yeah, I'm I I know there were
  2669. 1:42:39discussions that we had about
  2670. 1:42:42sort of
  2671. 1:42:44stopping using the three series
  2672. 1:42:45platform, working to get the four series
  2673. 1:42:47into the FDA, and then our
  2674. 1:42:50our hope and goal was that we would be
  2675. 1:42:51putting all the tests on that platform
  2676. 1:42:53as fast as we could.
  2677. 1:42:55Okay. So, do you know whether Mr.
  2678. 1:42:57Balwani knew that the TSPU was only
  2679. 1:42:59running something like 12 or 15 tests
  2680. 1:43:02at the time?
  2681. 1:43:04I I don't know. Um but I I assume he
  2682. 1:43:07would have.
  2683. 1:43:08Um why do you say that you assume he
  2684. 1:43:10would have?
  2685. 1:43:11Because he was managing the clinical
  2686. 1:43:12lab.
  2687. 1:43:14Um what about others at the company?
  2688. 1:43:17Um
  2689. 1:43:18did you ever discuss the fact that the
  2690. 1:43:19TSPU was running about 12 tests with,
  2691. 1:43:22for instance,
  2692. 1:43:23I I don't think I ever had a specific
  2693. 1:43:26discussion about the number of tests on
  2694. 1:43:28the TSPU with him that I I recall. Um
  2695. 1:43:32Uh we had a lot of discussions about
  2696. 1:43:35technology and including the TSPU. So,
  2697. 1:43:38it may have been an element of the
  2698. 1:43:39discussion, but I can't remember a
  2699. 1:43:41specific discussion about it only
  2700. 1:43:42running 12.
  2701. 1:43:44What about the project manager? Did she
  2702. 1:43:46ever discuss with them the fact that the
  2703. 1:43:48TSP was running something like 12 to 15
  2704. 1:43:50tests?
  2705. 1:43:53I I don't think so. I mean, what the
  2706. 1:43:55chemistries were running on in the
  2707. 1:43:57clinical lab was not a focus of
  2708. 1:43:59any of our discussions internally or or
  2709. 1:44:01really externally at at that point in
  2710. 1:44:03time.
  2711. 1:44:04Why wasn't it a focus of discussions?
  2712. 1:44:07Because in phase one of our model, it
  2713. 1:44:08was about the chemistries. It was about
  2714. 1:44:10redeveloping the assays to work with
  2715. 1:44:12small volumes. And then phase two
  2716. 1:44:15was about use of the the TSPU in a
  2717. 1:44:17distributed setting. And
  2718. 1:44:19that was the vision. That was what we
  2719. 1:44:21were spending most of our time working
  2720. 1:44:22on. But how we operationalized the tests
  2721. 1:44:25in the clinical lab
  2722. 1:44:27in the meantime was was just not
  2723. 1:44:31not something that any of us really
  2724. 1:44:33focused on very much
  2725. 1:44:35in in conversation.
  2726. 1:44:36So,
  2727. 1:44:37so can you explain for me I guess what
  2728. 1:44:40why Theranos decided to pursue
  2729. 1:44:42commercial testing in phase one. So, so
  2730. 1:44:45so I I I think I understand what you you
  2731. 1:44:46described there. Phase one is about
  2732. 1:44:48getting the chemistries ready. Phase two
  2733. 1:44:49is about the TSPU being out there.
  2734. 1:44:52W- why conduct commercial testing in in
  2735. 1:44:55phase one at all?
  2736. 1:44:57Yeah, so um
  2737. 1:45:01I I think there's there's two parts to
  2738. 1:45:03that. Um the first is um
  2739. 1:45:07our business model
  2740. 1:45:09shifted when we formed the partnership
  2741. 1:45:12after we formed the partnership with the
  2742. 1:45:13retail pharmacies. And there was a lot
  2743. 1:45:16of discussion about getting CLIA waiver
  2744. 1:45:19on the devices and a concern about how
  2745. 1:45:22long that would take and the regulatory
  2746. 1:45:24model for it. No one had done this
  2747. 1:45:27before.
  2748. 1:45:28And so, the decision was made to become
  2749. 1:45:30a clinical lab. The concept with phase
  2750. 1:45:32one was that the value is the retail
  2751. 1:45:36footprint, right? Bringing lab to the
  2752. 1:45:38retail footprint. And you've seen now
  2753. 1:45:41Quest and LabCorp, you know, immediately
  2754. 1:45:43go partner with
  2755. 1:45:45Walgreens and Walmart to to do that.
  2756. 1:45:48To the extent we were focused on small
  2757. 1:45:50samples, we invented the nanotainer
  2758. 1:45:53to be able to work with the chemistries
  2759. 1:45:56that we had redeveloped for small
  2760. 1:45:57assays. And that was the concept for
  2761. 1:46:00fingerstick-based testing in phase one.
  2762. 1:46:02In phase two,
  2763. 1:46:04the value proposition was to bring the
  2764. 1:46:06device to the wellness centers to get
  2765. 1:46:08tests even faster. And so, that's what
  2766. 1:46:12TSPU was about because it processed one
  2767. 1:46:15sample at a time. And in phase one, you
  2768. 1:46:17were going to have a lot of samples
  2769. 1:46:19coming in at the same time.
  2770. 1:46:20So,
  2771. 1:46:21phase one was retail footprint, access,
  2772. 1:46:23low cost, transparent pricing, the $4
  2773. 1:46:26lab test concept. And then to the extent
  2774. 1:46:28you were doing small samples, the
  2775. 1:46:30nanotainer implemented with our
  2776. 1:46:32chemistries.
  2777. 1:46:33And then phase two was
  2778. 1:46:36distribute the device, right? And and
  2779. 1:46:37phase two
  2780. 1:46:39was what we really wanted to do and is
  2781. 1:46:41what we're
  2782. 1:46:42still trying to do right now.
  2783. 1:46:47Is there a business plan or anything
  2784. 1:46:48that articulated that?
  2785. 1:46:50What you just
  2786. 1:46:51I'm
  2787. 1:46:52not in a
  2788. 1:46:55systematic way at that time. We
  2789. 1:46:58did not have um
  2790. 1:47:03organized documents the way we do now
  2791. 1:47:05that really lay all of this out.
  2792. 1:47:16Can you put that aside?
  2793. 1:47:18Actually, let's make a separate pile.
  2794. 1:47:21Put there. Thanks.
  2795. 1:47:59Let me see what's been marked. There it
  2796. 1:48:02is. Exhibit 200.
  2797. 1:48:11Just tab that.
  2798. 1:48:17Exhibit 200
  2799. 1:48:19reports to be Defendant Theranos Inc.'s
  2800. 1:48:22first supplemental responses and
  2801. 1:48:23objections to Plaintiff's first set of
  2802. 1:48:25interrogatories
  2803. 1:48:27uh in the filed in the Court of Chancery
  2804. 1:48:30of the State of Delaware in the Partner
  2805. 1:48:32Investments versus Theranos Inc. case
  2806. 1:48:35with starting Bates number
  2807. 1:48:36SEC-PRM-E-0005120.
  2808. 1:48:42Have you seen Exhibit 200 before?
  2809. 1:48:46I don't know. Um but again, I I I worked
  2810. 1:48:49with our legal teams as we worked to
  2811. 1:48:52respond to CFM.
  2812. 1:48:58So, if you take a look at 5128,
  2813. 1:49:07there's a supplemental response to that
  2814. 1:49:08same interrogatory that we were just
  2815. 1:49:10looking at
  2816. 1:49:12in Exhibit 199.
  2817. 1:49:14Interrogatory number 15.
  2818. 1:49:16Mhm.
  2819. 1:49:16Um and it says here, "By way of further
  2820. 1:49:19response, Theranos states the version
  2821. 1:49:213.5 of the SPU is the only version of
  2822. 1:49:23the SPU used since January 1st, 2013 to
  2823. 1:49:27process blood tests for commercial
  2824. 1:49:28testing certain patients." And that's
  2825. 1:49:30consistent with your understanding that
  2826. 1:49:31the TSPU version 3.5 was the only device
  2827. 1:49:34ever used for patient testing. Is that
  2828. 1:49:36right?
  2829. 1:49:38The only
  2830. 1:49:40version of the mini lab family that was
  2831. 1:49:42used, yes.
  2832. 1:49:42The only device manufactured by Theranos
  2833. 1:49:45is that that was used for patient
  2834. 1:49:46testing, is that right?
  2835. 1:49:48Um,
  2836. 1:49:49that's right. And just for the sake of
  2837. 1:49:52being explicit, we we considered
  2838. 1:49:55the we actually injection molded and
  2839. 1:49:57made the little cups that went into the
  2840. 1:49:59hardware ourselves in our factory. So,
  2841. 1:50:01we considered ourselves as manufacturing
  2842. 1:50:03some elements of the hardware for the
  2843. 1:50:05other platforms as well.
  2844. 1:50:06Okay. So, the sample cups that you were
  2845. 1:50:08using with the Abaxis 100, they those
  2846. 1:50:12were Theranos manufactured cups.
  2847. 1:50:15We We made them. Yep.
  2848. 1:50:17What were those called internally at the
  2849. 1:50:18time?
  2850. 1:50:20So, I don't know. Um, I've seen a lot of
  2851. 1:50:23references to
  2852. 1:50:24different um
  2853. 1:50:27words used, I think, in describing the
  2854. 1:50:28general concept. Um, I've seen the word
  2855. 1:50:31teacup. I I don't know if that
  2856. 1:50:34um explicitly refers to what I'm
  2857. 1:50:36referring to. I I had understood that to
  2858. 1:50:38refer to Theranos cup. Um, but I I could
  2859. 1:50:41be wrong about that.
  2860. 1:50:46Okay. Um,
  2861. 1:50:49and then if you turn to
  2862. 1:50:55And actually, um, yeah, turning to the
  2863. 1:50:57next page, 5129.
  2864. 1:51:02Actually, at the bottom of 5128, if you
  2865. 1:51:04want to follow through, it says, "By
  2866. 1:51:05further By way of further response,
  2867. 1:51:07Theranos identifies all other iterations
  2868. 1:51:09of the SPU since January 1st, 2013 as
  2869. 1:51:13follows and then there's a list on 5129.
  2870. 1:51:17Um which lists, you know, 3.0, the 4.0,
  2871. 1:51:21the mini lab tower, the 4S, and the 4.1.
  2872. 1:51:26Um
  2873. 1:51:27if you take a quick review of that
  2874. 1:51:29of the descriptions of all of those
  2875. 1:51:31versions, is this consistent with your
  2876. 1:51:33understanding of
  2877. 1:51:35those versions and what they were used
  2878. 1:51:37for?
  2879. 1:51:43I I I think so generally. I I don't have
  2880. 1:51:46any reason to doubt it.
  2881. 1:51:47Okay.
  2882. 1:51:49Um and what did the TSPU
  2883. 1:51:52look like? And maybe they were different
  2884. 1:51:55they looked differently, so what did the
  2885. 1:51:573.5 look like?
  2886. 1:52:00So they all
  2887. 1:52:01look like a box with a screen on it uh
  2888. 1:52:04with a hole on the front that has a door
  2889. 1:52:07and you can stick um what we call a
  2890. 1:52:10cartridge, which is the piece of plastic
  2891. 1:52:11that has all the chemicals in it, into
  2892. 1:52:14it um and the cartridge has a little
  2893. 1:52:17hole where you can put samples, so you
  2894. 1:52:19can put urine or you can put blood from
  2895. 1:52:22your arm, or you can put the little
  2896. 1:52:23nanotainers with the finger stick in
  2897. 1:52:25there.
  2898. 1:52:26And you said they all look very
  2899. 1:52:28similarly.
  2900. 1:52:30Generally, yes.
  2901. 1:52:31Generally.
  2902. 1:52:32Um
  2903. 1:52:33what was the size of one of the 3.5s?
  2904. 1:52:38What were the dimensions what were the
  2905. 1:52:39what were the were the dimensions of
  2906. 1:52:41that
  2907. 1:52:41I I don't I don't know the specific
  2908. 1:52:43dimensions, but we would sort of refer
  2909. 1:52:45to it as being similar in size to a a
  2910. 1:52:48desktop computer that you would have
  2911. 1:52:49under your desk.
  2912. 1:52:52Um and then turning to 5155
  2913. 1:52:59and exhibit 200.
  2914. 1:53:14You'll see there's a supplementer a
  2915. 1:53:16supplemental response in interrogatory
  2916. 1:53:18number 27. Do you see that?
  2917. 1:53:21I do.
  2918. 1:53:21Um and what PFM is asking Theranos is to
  2919. 1:53:25identify any non-proprietary or
  2920. 1:53:27commercially available machine equipment
  2921. 1:53:29or technology that you use to perform
  2922. 1:53:30tests.
  2923. 1:53:33Do you see that?
  2924. 1:53:34Yes.
  2925. 1:53:34Okay. And on the next page, Theranos
  2926. 1:53:36provides its response with a table
  2927. 1:53:39devices purchased from third parties and
  2928. 1:53:41it goes from 5156 to 5158.
  2929. 1:53:47Is this consistent with your
  2930. 1:53:48understanding of the third party devices
  2931. 1:53:51that Theranos was using to conduct
  2932. 1:53:53patient testing?
  2933. 1:53:55You know, I I wouldn't know um but I
  2934. 1:53:57don't have reason to doubt this
  2935. 1:53:58document.
  2936. 1:54:04And was that also your understanding um
  2937. 1:54:06you know, in 2014 that this was as as of
  2938. 1:54:092013 or since January 1st, 2013 but
  2939. 1:54:14um would this list be uh of devices that
  2940. 1:54:17were were being used by Theranos that
  2941. 1:54:19were purchased from third party
  2942. 1:54:22companies? Was that consistent with your
  2943. 1:54:24understanding as of 2014?
  2944. 1:54:27Again, I wouldn't know. I I
  2945. 1:54:29didn't have direct involvement in what
  2946. 1:54:31devices were being procured for the
  2947. 1:54:33clinical lab.
  2948. 1:54:34But you don't have any reason to believe
  2949. 1:54:35that um this information is incorrect as
  2950. 1:54:37of 2014 either.
  2951. 1:54:41I I don't know. I I don't know. I know
  2952. 1:54:43that the business model shifted.
  2953. 1:54:46Um I know that as of a period of time we
  2954. 1:54:48were
  2955. 1:54:50understanding the value proposition on
  2956. 1:54:53low cost and therefore trying to achieve
  2957. 1:54:56automation and standardization in the
  2958. 1:54:57clinical lab. So there was a big
  2959. 1:54:59investment in standardizing on Siemens
  2960. 1:55:01equipment. I don't know when exactly
  2961. 1:55:03that happened, so it
  2962. 1:55:05I'm
  2963. 1:55:06these might have been different in in
  2964. 1:55:08different periods of time.
  2965. 1:55:11Do you want to switch the tape?
  2966. 1:55:17We break for lunch at 12:30 today.
  2967. 1:55:20We've got 2 minutes left on this.
  2968. 1:55:21Yeah.
  2969. 1:55:21Yeah. No, why don't we Why don't we
  2970. 1:55:23switch the tape? If you guys don't mind,
  2971. 1:55:25go ahead and switch the tape. We are off
  2972. 1:55:27the record and
  2973. 1:55:28This concludes media number two of
  2974. 1:55:30Elizabeth Holmes. We're off the record
  2975. 1:55:31at 12:43.
  2976. 1:55:34Um
  2977. 1:55:36Let me just

About this transcript

This page contains the full transcript of Elizabeth Holmes SEC Deposition JULY 11, 2017 2 OF 4 redacted by ANTL Media, generated from the public captions YouTube serves with the video. The transcript has 16,016 words across 2,977 segments, with the original timestamps preserved so you can click any line to jump to that moment in the embedded player.

What you can do with it

Use the transcript to take notes, quote the speaker, build a study guide, generate a summary with ChatGPT or Claude via the YouTube Summary tool, or export it as a timed subtitle file with YouTube to SRT. You can also re-open it in the transcriber to choose a caption track available on the video.

Free YouTube transcript tool

YouTube2Text is a free YouTube transcript generator — no signup, no daily limit. Paste any YouTube link and get the full transcript instantly, with timestamps, click-to-jump, caption language selection, AI prompts for ChatGPT, Claude, and Gemini, and exports to TXT, SRT, VTT, or Markdown.